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ABSTRACT
ENVIRONMENTAL RISK FACTORS FOR INFLAMMATORY BOWEL
DISEASE: TRICLOSAN AND OTHER CONSUMER ANTIMICROBIALS
SEPTEMBER 2019
KATHERINE ZABALA SANIDAD, B.S., STONY BROOK UNIVERSITY
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Guodong Zhang

Inflammatory bowel disease (IBD) has become a serious health problem since the
incidence and prevalence of IBD has dramatically increased throughout the world. There
is evidence that environmental factors are primarily responsible for the increase of IBD,
therefore, it is important to identify novel environmental risk factors to reduce the risk of
IBD and its associated diseases. Antimicrobials used in consumer products might serve as
environmental risk factors for IBD and its associated diseases. Triclosan (TCS),
triclocarban (TCC), benzalkonium chloride (BAC), benzethonium chloride (BET), and
chloroxylenol (PCMX) are widely used antimicrobial ingredients in consumer products
and are ubiquitous contaminants in the environment. In 2016, the FDA removed TCS and
TCC from over-the-counter handwashing products while allowing additional time to
develop new safety and efficacy data for BAC, BET, and PCMX. Therefore, it is
important and timely to better understand the effects of these antimicrobials on human
health. Currently, there not much known about how chronic exposure to low-dose
consumer antimicrobials affects gut health. Here, using various in vitro and animal
models, we found that: 1) TCS is metabolically re-activated in the gut by the actions of
gut microbiota, leading to the accumulation of microbiota-derived toxic metabolites in
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the colon and resulting in gut-specific toxicity; 2) exposure to low-dose TCC exaggerated
the severity of colitis and exacerbated the development of colitis-associated colon
tumorigenesis, via gut microbiota-dependent mechanisms; and 3) exposure to low doses
of BAC, BET, and PCMX, increases dextran sodium sulfate (DSS)-induced colonic
inflammation and exposure to BAC increases azoxymethane (AOM)/DSS-induced colon
tumorigenesis in mice. Together, these results support that chronic exposure to consumer
antimicrobials could be a novel risk factor for colitis and colitis-associated colon cancer
through gut microbiota-dependent mechanisms. A better understanding of the impact
antimicrobials on human health, specifically gut health, could lead to significant
influence on public health and regulatory policies.
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CHAPTER 1
INTRODUCTION

1.1 Environmental risk factors for inflammatory bowel disease
Inflammatory bowel disease (IBD), characterized by chronic inflammation within
the small and large intestines, has become a serious health problem. The incidence and
prevalence of IBD has dramatically increased in the United States and other countries,
and currently there is no cure for IBD 1. Another concern for IBD patients is that they
have an increased risk for developing colon cancer. In fact, more than 20% of IBD
patients will develop and more than 50% of those patients will die from colon cancer 2.
There is evidence that environmental factors are primarily responsible for the increase of
IBD 3-5; therefore, it is important to identify novel environmental risk factors to reduce
the risk of IBD and its associated diseases.
One environmental factor suggested to increase IBD are antimicrobial agents
through modulation of the gut microbiome. It is well established that oral antibiotic
drugs, at therapeutic doses, can modulate gut microbiota to regulate colonic inflammation
6,7

. However, it is not known how chronic exposure to low-dose consumer antimicrobials

affects gut health. Here, we will focus on the consumer antimicrobials triclosan (TCS),
triclocarban (TCC), benzalkonium chloride (BAC), benzethonium chloride (BET), and
chloroxyenol (PCMX) (see chemical structures in Figure 1). We will discuss their
exposure into the environment as well as their effects on the gut microbiome and gut
health in animal models and humans.

1

1.2 Antimicrobials in the consumer products and the environment
During the past two decades, antimicrobial-containing products have increased in
the U.S. and other countries 8. The two most common antimicrobials highly produced are
triclosan (TCS) and triclocarban (TCC). TCC was introduced in 1957 as an antifungal
and antibacterial compound specifically used against resistant forms of Staphylococcus
aureus (MRSA) and Enterococci (VRE) 8. Later in 1964, TCS was introduced as a broadspectrum bacteriostatic and fungicidal agent. TCS has antimicrobial activity due to its
inhibition of the FabI enzyme which inhibits fatty acid synthase in microorganisms 9.
TCC and TCS are incorporated into consumer products like soap, toothpaste, mouthwash,
clothes, kitchenware, and toys. They are also used in deodorants, polymers, and fibers 10.
When antimicrobial compounds are typically disposed, they usually are
transported through drainage systems to wastewater treatment plants (WWTPs) where
they can be removed from water that will end up being discharged into surface waters 8.
When released into the environment, TCS has been shown to be transformed into methylTCS by certain bacteria such as Rhodococcus, Acinetobacter, and Mycobacterium under
aerobic conditions, and TCS can also go through photodegradation 11-14.
Despite their fates in WWTPs, TCS and TCC have been reported to break through
WWTPs to disperse into surface waters at ng/L concentrations. In addition, the two
antimicrobials are can also accumulate in carbon- and lipid-rich sewage sludge, which is
then deposited in landfills or applied onto land 15. Because of this, TCS and TCC has
been detected in the environment in the United States and various other countries. In
2014, they were known to be part of the top 10 contaminants in U.S. rivers 8. TCS has
been detected in Indiana stream waters 16. In Germany, TCS and methyl-TCS was
2

detected in the surface water, fish, and suspended particulate matter in rivers 17,18. TCS
has been found in the surface waters of Washington D.C. and Switzerland 19,20. Both TCS
and TCC were also detected in the soil of fields that receive sewage sludge in Ohio and
the United Kingdom 13,21. They were also detected in earthworms and biosolids in
Ottowa, Canada 22. TCS can also be detected in biosolids in North Carolina and
California that could be potentially used for farming 23. TCC has been detected in Lake
Greifensee sediments in Switzerland 24.
Both TCS and TCC appear to last long in the environment. TCS detected in the
surface water in Germany was found to have an 11 day half-life 17,18. Another study
showed that the TCS and TCC that were detected in field soil had a half-life of 20-58
days and may last even longer 13,21. Interestingly, TCC, TCS, and methyl-TCS were
detected in earthworms four years after applying TCS- and TCC- containing biosolids
into an environment in Ottowa, Canada 22.
Due to their widespread contamination and longevity in the environment, TCS
and TCC were detected in both aquatic life and food crops. TCS was found in salmon
25,26

while TCC was absorbed by freshwater mussels 27. Both TCS and TCC have been

reported to accumulate in crops and vegetables like soybean plants that were planted in
contaminated soil and irrigated with contaminated water 28-31. TCS and TCC were also
found in the roots and shoots of crops such as broccoli, potato, beats, cabbages, and
peppers. The root tissues of the plants accumulated greater than 100 ppm TCC, while
onions accumulated greater than 800 ppm in their bulbs. TCS and methyl-TCS was found
in the roots of certain vegetables 32.

3

Benzalkonium chloride (BAC), benzethonium chloride (BET), and chloroxylenol
(PCMX) are other antimicrobial compounds that are potential replacements of TCS and
TCC in consumer products. BAC, BET, and PCMX are antimicrobial ingredients used in
many cleaning products and surface disinfectants that are widely used in public spaces
including workspaces, hospitals, and homes 33,34. They are also used in hand hygiene or
skin antiseptics, with concentrations of 250-500 mg/L 34-36. In addition to being used in
hand soaps and dish soaps, PCMX has also been used as a pesticide 34. Previous studies
have shown that BAC and BET were also frequently detected at high levels in grapefruit
seed extract (GSE), a common dietary supplement, with 5 out of 6 commercial GSE
products containing 1.3-10% of BET37,38. Because of the widespread use of these
compounds, BAC and BET were also detected in various environments. They were
detected in river water, sewage effluent, urban estuarine sediment, and stormwater
samples 39-41. The release of these antimicrobials into the environment raise concerns
regarding their exposure to and impacts on human health and the environment 37-45.

1.3 Human exposure to antimicrobials
Various antimicrobials have been detected frequently detected in the human body.
Between 2003-2004, TCS was detected in 75% of urine samples of individuals in the
United States (TCS concentration = 7.9 nM-13.1 µM) 46. TCS has also been detected in
urine samples (TCS concentration = 0.08-0.71µM) in Queensland, Australia 47 and in
Quebec, Canada 48. In 2013-2014, 36.9% of urine samples in the United States contained
>0.1 µg/L of TCC 49. Both TCS and TCC were detected in the urine samples of people in
China 50 as well as in the serum of women 51. TCC reportedly reached a concentration of
4

~500 nM in the plasma of humans using TCC-containing personal care products 52. Both
TCS and TCC were also found in the blood of pregnant women and their newborns in an
urban population from Brooklyn, NY 53 and in the urine of pregnant women in Canada 54.
BAC has also been detected in the serum of a patient who accidentally ingested the
antimicrobial 43. There have been no recent studies about whether BET or PCMX have
been found in humans, but that may change with the increase use of these antimicrobials.
The average human intake levels of TCS from using consumer products was
estimated to be 0.047-0.073 mg/kg/day; in mice it would be equivalent to 0.56-0.88
mg/kg. Men, women, and children, are exposed to 0.047, 0.065, and 0.073 mg/kg/day,
respectively 55. Data from previous studies was used to extrapolate TCS tissue exposure
levels from consumer products: according to data from two studies, dermal exposure to
TCS can lead to 0.4-64 nmol TCS/mg tissue 56-58. Because antimicrobials are found quite
often in human tissues, it is important to understand different routes by the compounds
that might lead to human exposure.
Because TCS is used in certain toothpastes, exposure to the antimicrobial can
occur orally in humans 26. Previous human studies had shown that using TCS-containing
toothpaste daily for weeks increased the plasma concentrations of TCS (a combination of
TCS and TCS-glucuronide) from 0.03–2.7 nM to 90–1,000 nM 59,60. Other studies also
showed that oral exposure to TCS via TCS-containing toothpaste or mouth rinse can
increased plasma levels of TCS in human subjects 61,62. Interestingly, a study showed that
mothers using TCS-containing toothpaste for 6-12 weeks had 0.4-38 ng/g TCS (a
combination of TCS and its conjugates, TCS-sulfate and TCS-glucuronide) in their
plasma and 0.022-0.95 ng/g TCS in their breast milk 63; this suggests that the young
5

infants being breastfed by those mothers can be orally exposed to TCS. In fact, two
studies reported that infants were orally exposed to TCS via the breast milk of mothers
exposed to TCS-containing personal care products 64,65.
Oral exposure to antimicrobials might also occur via food consumption. As
mentioned before, TCS and TCC has been reported to accumulate in crops and vegetables
28

. TCC was also shown to be uptaken by freshwater mussels 27. TCS, TCS-conjugates

(TCS-glucuronide, TCS-sulfate), and methyl-TCS found in catfish, salmon, and other fish
18,25,66

. BAC was found in food additives in minced meat and raw sausage batters 44.

Previous studies have shown that BAC and BET were frequently detected at high levels
in grapefruit seed extract (GSE), which is a common dietary supplement, though these
compounds are not permitted to use as food additives 37,38. This suggests that suggests
humans can be exposed to antimicrobials via the consumption of food and dietary
supplements.
Antimicrobials are also found in many different consumer products for topical
application. TCS is in deodorants thus allowing people to be exposed to the antimicrobial
via their skin 67. TCS absorption into the body can occur through dermal exposure as
shown in an in vitro study using human epidermal membranes 68. Another study also
showed TCS absorption through dermal exposure with TCS on human skin reaching
millimolar levels 57,69. The estimated TCS concentration in tissues after dermal
application is 14-67% of applied TCS dose 70.
TCS and TCC were active ingredients in many soaps which would allow another
route of dermal exposure; however, it was shown that TCS- and TCC-containing soaps
had no additional health benefits compared to soap without those antimicrobials 71, and
6

were therefore no longer allowed to be sold. The antimicrobials BAC, BET, and PCMX
are still allowed in hand hygiene or skin antiseptics, such as hand and dishwashing soaps,
suggesting a higher chance of dermal exposure to these compounds 34-36. They are also
used in many cleaning products and surface disinfectants

33,34

.

Humans can ultimately be exposed to antimicrobials through the environment, use
of antimicrobial-containing PCPs, as well as ingestion of certain food products. Because
this exposure in humans is prominent, it is important to understand their effects on human
health.

1.4 Effects of antimicrobials on health
There have been various in vitro and animal studies to understand the effects of
antimicrobials on human health. In fact, many of these studies have focused on
antimicrobials as endocrine disrupting chemicals; as agents that can facilitate
developmental and reproductive defects; as toxicants that can increase genotoxicity,
inflammation, and cancer; and as facilitators of antibacterial resistance to themselves as
well as other antibiotics.
Antimicrobials were shown to act as EDCs and increase developmental and
reproductive defects. TCS and TCC have been shown to be endocrine disrupting
chemicals (EDCs). In fact many studies have shown that both TCS and TCC can increase
androgenic activity in various in vitro assays and animal models 72-77. One study even
showed that TCC, TCS, and methyl-TCS can be EDCs in frog and mammalian cell
culture systems 78. Exposure to TCS resulted in sperm toxicity in male rats 79, while
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exposure to BAC and BET showed developmental defects in rodents and caused
reproductive dysfunction in mice

80,81

.

Antimicrobials were also shown to increase genotoxic and inflammatory
responses. Mice that were dermally exposed to TCS had increased immune cell
infiltration into the skin draining lymph node, suggesting a potential for allergic reactions
82

. Previous studies have shown that BAC increased pro-inflammatory cytokines in

immortalized human conjunctival and corneal epithelia cells 83, and also increased
proinflammatory cytokines, phagocytosis, and migration in THP-1 macrophages 84. BAC
also showed genotoxic and inflammatory effects in mammalian and plant cells and
rainbow trout at environmentally relevant concentrations 85,86. As mentioned before,
BAC, BET, and PCMX are three possible replacement antimicrobials for TCS and TCC.
Interestingly, one study had shown that these three antimicrobials have comparable
toxicities to TCS in C. elegans, greater toxicity in zebrafish embryos, and induce similar
neurotoxicity to TCC in fish embryos 87. In addition, PCMX has been shown to cause
DNA damage to erythrocytes of rainbow trout 88.
TCS and TCC have been shown to increase the progression of certain cancers.
TCS increased liver cancer in mice 89. TCS also increased ovarian cancer growth and the
progression of breast cancer via an estrogen receptor-dependent pathway in cellular and
mouse xenograft models 90,91. TCS can also increase cancer by potentiating the epithelialto-mesenchymal transition (EMT) in human lung cancer cells 92. TCS has also been
shown to promote cancer by stimulating the secretion of vascular endothelial growth
factor (VEGF) by human prostate cancer stromal cells 93. Chronic exposure to TCC was
demonstrated to promote carcinogenesis of human breast cells in vitro from non8

cancerous to pre-malignant 94, though more studies should be conducted to support its
carcinogenic effects.
Some antimicrobials have been associated with increased antibacterial resistance.
A study showed that TCS can contribute to antimicrobial resistance in Escherichia coli
strains 95. Another study showed that TCS can cause FabI mutations and antimicrobial
resistance in MRSA, clinical isolates of Staphylococcus aureus, E. Coli, and
Acinetobacter baumannii 96-100. TCS can also cause resistance to antibiotics in
Pseudomonas aeruginosa by selecting for mutant strains overexpression multidrug efflux
pumps 101. TCS exposure can increase its own resistance in benthic bacterial communities
102,103

. Aside from TCS, BAC and PCMX were also found to increase antibacterial

resistance. BAC was found to increase cross-resistance in strains and isolates of Pantoea,
Enterobacter, Staphylococcus, and Escherichia species to some antibiotics and other
biocidal agents 104. Environmental isolates of staphylococci in Massachusetts were also
found to be resistant to BAC, as well as erythromycin, penicillin, and ampicillin 105. In
addition, BAC, used in disinfectants in the food industry, was well tolerated by Listeria
monocytogenes isolates from some retail foods 106. PCMX was also tolerated and did not
appear to have an effect on certain Pseudomonas species found in industrial
environments 88. These results suggest that the application and exposure of these
antimicrobials in the environment are associated with antibacterial resistance. It would
be interesting to see if the antimicrobials would increase antibacterial resistance in the gut
microbiomes of animals and humans as well.
There have also been a few human studies of the effects of these antimicrobials,
mostly TCS. Human studies have shown and suggested that TCS exposure is associated
9

with allergies and asthma 107-109, which is supported by a study that showed TCS-induced
aggravation airway hyperresponsiveness in aeroallergen-sensitized mice 110. Interestingly,
one study also suggested that BAC can be a novel allergen, showing that between 19982010 the rate of allergic patch tests to BAC had increased 111. TCS was also shown to be
associated reproductive defects since a human study provided evidence that increased
TCS in the urine was associated with abnormal morphology in sperm 112. This study
supports the previous in vitro and animal studies showing TCS causing reproductive
defects. Another study suggested that increased serum concentrations of TCS may
influence the thyroid function of children, but not the women who were pregnant with
them 113, again, similar to s previous in vitro and animal studies supporting TCS as an
EDC. More human studies are needed to really investigate the effects of antimicrobials in
human health.

1.5 Effects of TCS on the gut microbiome and gut health
IBD has become a serious health problem; the incidence and prevalence of IBD
has dramatically increased throughout the world 1. Considering the growth rate of IBD
and the lethal consequence of IBD-associated colon cancer, it is of critical importance to
identify novel environmental risk factors to help reduce the risks posed by these diseases.
Modulation of the gut microbiome has been implicated in a lot of diseases, and gut
microbiota has been shown to contribute to colon inflammation 114,115. Here, we will
discuss consumer antimicrobials as environmental factors that can increase IBD, as well
as their effects on the gut microbiome and gut health.
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1.5.1

Effects of TCS on animal and human gut microbiomes
Many studies showed that TCS exposure is capable of modulating and disturbing

the gut microbiome in various animal models. In fathead minnows exposed to TCS for
one week, their gut microbial communities experienced a decrease in alpha diversity and
a modulation of their composition compared with gut microbial communities in
unexposed fish 116. The gut microbial communities of zebrafish exposed to TCS for one
week experienced a decrease in species richness 117. Gut microbiomes of adolescent rats
exposed to TCS were also had a reduction in the relative abundance of bacteria from the
phylum Firmicutes and an increase in bacteria from the phylum Bacteroidetes compared
with the gut microbiomes of unexposed rats 118. TCS exposure for 13 weeks decreased
species richness and also significantly modulated 9 groups of bacterial families in the gut
microbiomes of TCS-exposed mice compared with control mice 119. In other animal
studies, TCS exposure was found to also perturb the gut microbiome in aeroallergensensitized mice and BALB/c mice 110,120. Consistent with these previous studies, our
recent study showed that a 3-week treatment of TCS via diet reduced the diversity and
altered the composition of the gut microbiome in C57BL/6 mice 121. Altogether, these
results show that TCS can perturb the gut microbiome in various animal models.
In this study, the fish were exposed to low doses of TCS (0.1-1 ppb which is
equivalent to 0.35-3.45 nM) to mimic the levels of TCS detected in the aquatic
environment 116. The dose used in fathead minnows is quite low compared to the TCS
levels found in humans after toothpaste use (~90-1000 nM) 59,60, yet there was still a
potent effect on the gut microbiomes of these animals, suggesting that there may be a
similar effect in humans.
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Recent human studies support that routine exposure to TCS, through the use of
TCS-containing personal care products (PCPs) or consumption of TCS-containing breast
milk, can alter the human gut microbiomes. In one study, recent mothers who reported
using PCPs containing TCS provided both their breast milk and their infant stool samples
for evaluation of the infants’ gut microbiomes

64

. Interestingly, the gut microbiomes of

infants who received breast milk containing TCS had significantly lower alpha diversity
compared with infants who received breast milk with non-detectable levels of TCS. In
addition, the relative abundances of certain bacteria were modulated in the infants who
were fed TCS-containing breast milk 64. Another study, recent mothers were given
different TCS-containing PCPs that exposed individuals to TCS orally or dermally, and
the adult and infant gut microbiomes were evaluated 65. There was a decrease in the
diversity of mothers’ gut microbiomes and an increase in the relative abundance of
broadly antibiotic-resistant Proteobacteria species in adults 65. However, we need to
acknowledge that there are also inconsistent results. Some infants who consumed TCScontaining breast milk had similar gut microbiomes to infants receiving breastmilk not
containing TCS 65. Also, the gut microbiomes of human subjects exposed to TCS via
PCPs for 4 months were not significantly different from unexposed human subjects 122.
Altogether, animal studies, and some human studies, show that environmentally
relevant concentrations of TCS has been shown to modulate the gut microbiome.
However, these studies do not go further to discuss what the modulation of the gut
microbiome in these animal studies could mean in terms of animal and human health.
Modulation of the gut microbiome has been implicated in a lot of diseases including
metabolic diseases 114. Gut microbiota has also been shown to contribute to colon
12

inflammation 115. Therefore, our study aimed to further understand the effects of TCS on
the gut microbiome and how the gut microbiome plays a role in the pathogenesis of
colitis and colon cancer.

1.5.2

Effects of TCS on gut health
Our study sought to understand how TCS could affect diseases, specifically colitis

and colon cancer, through its modulation of the gut microbiome 121. Our recent study
showed that exposure to 10-80 ppm TCS via diet induced colonic inflammation,
exaggerated dextran sodium sulfate (DSS)- or Interleukin 10 (IL-10) knockout-induced
colitis, and exacerbated the development of azoxymethane (AOM)/DSS-induced colon
tumorigenesis in mouse models, suggesting that TCS has potential adverse effects on gut
health 121. Gut microbiota has been shown to contribute to colon inflammation 115, so we
evaluated the gut microbiome’s role in TCS-enhanced colitis. Compared with unexposed
mice, TCS-exposed mice had a decrease in the alpha diversity in their gut microbiomes
and a modulation of their gut microbial composition at phylum and genus levels 121.
These results are consistent with the previous animal studies summarized previously 116119

. Due to this, we wanted to see if this modulation of the gut microbiome by TCS

played a role in the proinflammatory effects of TCS.
Regarding the mechanisms by which TCS exposure exaggerates colonic
inflammation and colon cancer, our study supports that the gut microbiome plays an
essential role. Indeed, TCS exposure induces colonic inflammation in conventionally
raised mice, but not in mice lacking a gut microbiome (germ-free mice) or mice lacking
Toll-like receptor 4 (Tlr4-/- mice), a critical regulator of host-microbiome interactions.
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These results support that the gut microbiome is required for the pro-inflammatory effects
of TCS 121. Again, since substantial studies, including our current study, have shown that
TCS has potent effects to alter gut microbiome in animals 116-119 and human subjects 64,65,
we think that it is of critical importance to reassess the potential adverse effects of TCS
on the gut microbiome and gut health, in order to generate science-based regulatory
policies.
A critical question is whether the results observed in animal models could reflect
the responses of human exposure to TCS. The doses of TCS used in our study (10-80
ppm in diet) are among the lowest doses used in animal experiments of TCS 121,123. Using
LC-MS/MS, we found that after mice were exposed to 10–80 ppm TCS via diet for 3
weeks, the concentrations of TCS and its metabolite in mouse plasma were comparable to
the concentrations reported in the plasma of TCS-exposed human volunteers 59,60. In
addition, we treated mice for several weeks, while humans could be exposed to TCS for
many years. We have to point out that there are many challenges to use mouse models to
study human exposure to consumer chemicals, and there could be fundamental
differences in absorption, metabolism, secretion, and biological responses to TCS
between mice and humans 123. Together, these results support that it is essential to
evaluate the impact of TCS on gut health further.

1.6 Significance and hypothesis
The incidence and prevalence of IBD are dramatically increasing in the United
States and other countries, making IBD a serious health problem 1. Emerging evidence
supports that environmental factors are primarily responsible for the growing incidence
14

of IBD 3-5. Considering the growing incidences and potential lethal consequence of IBDassociated colon cancer, it is of practical importance to identify novel environmental risk
factors, in order to reduce the risks posed by IBD and associated diseases.
Triclosan (TCS) is an antimicrobial compound incorporated into many consumer
products, is frequently detected in the human body, and is an environmental contaminant
in the US 8,46. Our recent study showed that exposure to low-dose TCS exaggerates
colonic inflammation and exacerbates the development of colitis-associated colon
tumorigenesis in mouse models, suggesting that TCS could have adverse effects on gut
health 121. Exposure to TCS alters the gut microbiome and fails to induce colonic
inflammation in mice lacking a gut microbiome (germ-free mice), supporting that the gut
microbiome contributes to the pro-inflammatory effect of TCS 121. However, the
functional roles of the gut microbiota, as well as specific gut bacteria involved, in the
pro-inflammatory effects of TCS are unknown.
One functional role of the gut microbiota is its ability to metabolize xenobiotics.
Because TCS contains a phenolic structural moiety (-Ph-OH), it is highly susceptible to
Phase II metabolizing enzymes such as glucuronyl transferase and sulfotransferase.
Indeed, in vivo studies showed that TCS is rapidly metabolized by Phase II enzymes 124,
leading to the formation of TCS glucuronide and TCS sulfate which are water-soluble,
biologically inactive, and are rapidly secreted out of the body. However, TCS metabolism
in the colon has not been characterized. Determining the metabolites of TCS in the colon,
along with gut microbiota’s role in TCS metabolism, is important for understanding its
pro-inflammatory effects.
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The long-term goal of our research is to identify novel environmental risk factors
for IBD and associated colon cancer, in order to prevent these diseases. To achieve this,
the objective of this research is to validate the effects and mechanisms of triclosan, as
well as other consumer antimicrobials, and the gut microbiome on IBD. We hypothesize
that the gut microbiota is responsible for colonic metabolism of TCS, and that TCS itself,
but not its metabolites, are responsible for its biological activity. In addition, we
hypothesize that other consumer antimicrobials such as TCC, BAC, BET, and PCMX are
also able to have detrimental effects on gut health.
To test these hypotheses, we propose the following specific aims:
Aim 1. To characterize the major metabolites of TCS in the colon, determine the
role of the gut microbiome in TCS metabolism, and identify specific bacteria involved in
TCS metabolism.
Aim 2. To compare the biological effects of TCS and its metabolites.
Aim 3. To determine the effects of other antimicrobials (TCC, BAC, BET, and
PCMX) on gut health.
Our research can lead to the further understanding of the effects of these
antimicrobials on gut health, which may lead to a significant impact on regulatory
policies of these antimicrobials. Furthermore, this information may help us understand
more about what environmental factors play a role in IBD.

16

Figure 1.1: Chemical structures of triclosan (TCS), triclocarban (TCC),
benzalkonium chloride (BAC), benzethonium chloride (BET), and chloroxylenol
(PCMX).
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CHAPTER 2
METABOLIC REACTIVATION OF THE ENVIRONMENTAL TOXICANT
TRICLOSAN BY GUT MICROBIOTA

2.1 Introduction
Previous research regarding the metabolism of environmental toxicants and
pollutants has mainly focused on the metabolic processes in the mammalian host tissues.
Indeed, substantial research has shown that once the environmental compounds enter the
body, they are rapidly metabolized by Phase I and Phase II metabolizing enzymes, which
are commonly expressed in various host organs, resulting in the formation of
glucuronide- and sulfate-conjugates. These conjugates are usually water-soluble,
biologically inactive, and are rapidly removed from the body, leading to inactivation and
detoxification of the environmental compounds 125. Based on these findings, some
previous studies had suggested that due to the rapid metabolism and low stability of many
environmental compounds, exposure to low doses of these compounds is not likely to
cause adverse effects in vivo 126-129. However, most previous research has only focused on
the metabolic reactions in the host tissues 125, while the gut microbiota-mediated
biotransformation is understudied 130,131.
Emerging research supports that gut microbiota play critical roles in xenobiotic
metabolism 130,131. The microbiota can catalyze highly unique metabolic transformations,
such as hydrolytic (e.g. de-glucuronidation and de-sulfatation), reductive (e.g. C=C or
N=N bond reduction), functional group transfer (e.g. methyl or acetyl transfer), and
radical-mediated reactions 131. Many of these metabolic reactions are distinct from
18

reactions of the host enzymes, resulting in colonic accumulation of microbiota-derived
metabolites which could have unique activities and toxicities 131. These studies suggest
that compared with other organs, the gut tissue could have a completely different profile
of xenobiotic metabolism due to the presence of gut bacteria, resulting in potential gutspecific toxicology. However, to date, the metabolism of environmental toxicants and
pollutants in the gut tissue and the roles of gut microbiota involved are mostly unknown.
Triclosan (TCS) is a high-volume chemical used as an antimicrobial ingredient in
more than 2,000 consumer products: every year, several million pounds of TCS are used
in the United States 8. Due to its widespread application and persistence, it has caused
pollution ubiquitously in the environment and is frequently detected in the human
population, raising concerns about its impacts on the environment and human health 8.
Our recent research shows that exposure to TCS, at doses relevant to human exposure,
enhances basal colonic inflammation, increases the severity of inflammatory bowel
disease (IBD), and exaggerates IBD-associated colon tumorigenesis in mice 121. The
adverse effects of TCS require the presence of gut microbiota since TCS exposure fails to
promote colonic inflammation in germ-free mice 121. However, the functional roles of the
gut microbiota involved are unknown. In this study, we used liquid chromatographytandem mass spectrometry (LC-MS/MS) to profile TCS metabolism in mouse models, in
vitro culture of gut bacteria, and human subjects, to study the functional roles of gut
microbiota in the gut metabolism of TCS.
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2.2 Materials and Methods
2.2.1

Chemicals
Triclosan (TCS, 99% purity) was purchased from Alfa Aesar (Haverhill, MA).

TCS glucuronide (95% purity) and TCS sulfate (95% purity) were purchased from
Toronto Research Chemicals (Toronto, ON, Canada).

2.2.2

DNA extraction
DNA was extracted from mouse fecal samples and human stool using QIAmp

DNA Stool Mini Kit (Qiagen, Valencia, CA) following instructions from the
manufacturer with an additional bead-beating step. The quantity of the extracted DNA
was measured using a NanoDrop Spectrophotometer (Thermo Fisher Scientific), and the
quality was verified using gel electrophoresis. The DNA was then subjected to further
analysis.

2.2.3

Real-Time PCR analysis of 16S rRNA gene and strain-specific bacteria
primers
DNA extracted from mouse fecal samples were subjected to qPCR analysis

using a DNA Engine Opticon system (Bio-Rad Laboratories, Hercules, CA). 20 µL
PCR reactions were made using the Maxima SYBR_green Master Mix (Thermo Fisher
Scientific), and DNA was normalized to 5 ng/µL per reaction. The 16S rRNA primers
and strain-specific bacteria primers are listed in Table 2.1.
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2.2.4

Isolation of bacteria from mouse tissues and human stool samples
Mouse tissues (small intestine, cecum, colon, and feces) were harvested from

mice, and human stool samples were collected. The tissues and stool were dissolved in
sterile PBS with 0.05% L-cysteine, then centrifuged at 900xg for 5 min. The
supernatant containing culturable bacteria was then fermented at 37 oC in MRS broth
in an anaerobic cabinet (Whitley A35 anaerobic work station, Don Whitley Scientific)
under an atmosphere of 85% N2, 10% CO2, and 5% H2. In addition, the remaining
supernatant (~0.6 mL) containing culturable bacteria was then mixed with sterile 50%
glycerol (0.3 mL) and stored at -80 oC as stock for future experiments.

2.2.5

In vitro fermentation of bacteria
The bacterial strains (Lactobacillus strains: L. brevis 14869, L. Sakei 11146, L.

reuteri DSM 20016, L. rhamnosus ATCC 7469, L. gasseri 33323, L. reuteri DSM
20053; Bifidobacterium strains: B. animalis subsp. animalis 25527, B. breve 15700, B.
bifidum 29521, B. infantis 15697, B. longum 15707, B. pseudocatenulatum) were
obtained from the Agriculture Research Service Culture Collection (NRRL). Strains
and isolated bacteria from mouse tissues and human stool samples were fermented at
37 oC in MRS broth in an anaerobic cabinet (Whitley A35 anaerobic work station, Don
Whitley Scientific) under an atmosphere of 85% N2, 10% CO2, and 5% H2. When the
OD600 reached 0.5, bacteria were then inoculated 1:10 into MRS broth containing
either DMSO vehicle, 20 µM TCS, or 20 µM TCS glucuronide. After 48 h, the samples
were collected and stored in -80 oC for further analysis.
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2.2.6

Growth curves of pure bacteria
Pure strains of bacteria (listed above) were fermented at 37 oC in MRS broth in

an anaerobic cabinet (Whitley A35 anaerobic work station, Don Whitley Scientific)
under an atmosphere of 85% N2, 10% CO2, and 5% H2. When the OD600 reached 0.5,
bacteria were inoculated 1:100 into MRS broth containing either DMSO vehicle, TCS
(0.1-1 µM), or TCS glucuronide (20 µM) in a 96-well plate. Theplate was entered into a
plate reader, and the OD600 was measured from 0-30 h.

2.2.7

Human urine and stool collection
Human urine and stool samples from a previous study 122 were utilized

(schematic of human urine and stool sample collection is shown in Figure 2.9A).
Briefly, healthy human volunteers from Stanford University were given personal care
products either containing or not containing TCS. Urine and stool samples were then
collected from the volunteers before and 1-4 months after using the personal care
products. The study was approved by the Institutional Review Board of Stanford
University (ClinicalTrials.gov identifier NCT01509976).

2.2.8

Extraction of TCS metabolites
Mouse tissues and human stool were placed in homogenizer tubes with beads

and 1 mL methanol, then homogenized using a bead-disruptor (OMNI International,
Kennesaw, GA). Samples were centrifuged at 10,000 rpm at room temperature for 3
min. The supernatant was collected and then centrifuged again at 14,000 rpm at room
temperature for 5 min. 500 µL of the supernatant was then collected and vacuum22

centrifuged to dryness. For bacterial broth (50 µL) and human urine (100 µL), each
sample was combined with 1 mL methanol and placed on ice. After 10 min on ice,
samples were centrifuged at 14,000 rpm at room temperature for 5 min. 500 µL of the
supernatant was then collected and vacuum- centrifuged to dryness. The extracts were
re-dissolved in methanol with amount that was proportional to sample weights or
volumes, then centrifugated (14,000 rpm, 15 min, 4℃) before the LC-MS/MS analysis.

2.2.9

Detection of TCS and TCS metabolites by LC-MS/MS
TCS, TCS glucuronide, and TCS sulfate in the samples were quantified using a

Thermo Scientific Dionex Ultimate 3000 ultrahigh performance liquid chromatography
(UHPLC) system coupled with a TSQ Quantiva Triple Quadrupole Mass Spectrometer.
ACQUITY UPLC C18 column (1.7 μm particles, 2.1 mm × 100 mm, Waters) was used
for chromatographic separation. Data acquisition was performed by multiple reaction
monitoring (MRM) mode.
Hydroxyl-TCS, hydroxyl-TCS glucuronide, and hydroxyl-TCS sulfate were
monitored by a Thermo Scientific Dionex Ultimate 3000 UHPLC system coupled with
an Orbitrap Fusion Tribrid Mass Spectrometer. Chromatographic separation was
achieved on an ACQUITY UPLC HSS T3 column (1.7 μm particles, 2.1 mm × 100
mm, Waters). Targeted MS2 mode was used for metabolite identification. Details of
the instrumental methods are provided in Table 2.2-3 The data were analyzed using
Xcalibur software (version 4.1, Thermo Fisher Scientific).
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2.2.10 Cell culture and treatment with TCS, TCS glucuronide, and TCS sulfate
MC38 mouse colon cancer cells were cultured in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and incubated at
37 oC under an atmosphere of 5% CO2. MC38 cells were seeded at 20% confluency
and left to settle overnight. Cells were then treated with either 1 µM TCS, TCS
glucuronide, TCS sulfate, or vehicle (DMSO). After 48 h, cells were harvested for RTqPCR analysis, and cell medium was collected for ELISA analysis.

2.2.11 Reverse-Transcriptase-qPCR of inflammatory biomarkers
Total RNA was isolated from them using Trizol reagent (Ambion) according to
the manufacturer’s instruction. RNA was reverse transcribed into cDNA using the High
Capacity cDNA Reverse Transcription kit (Applied Biosystem) according to the
manufacturer’s instructions. 20 µL PCR reactions were prepared using the Maxima
SYBR_green Master Mix (Thermo Fisher Scientific), and qPCR was carried out using
a DNA Engine Opticon system (Bio-Rad Laboratories). Mouse-specific primer
sequences (Thermo Fisher Scientific) used to detect inflammatory biomarkers are listed
in Table 2.1. Gapdh expression was used as an internal control.

2.2.12 ELISA of inflammatory biomarkers
Cell medium from MC38 colon cancer cells treated with either 1 µM TCS, TCS
glucuronide, TCS sulfate, or vehicle (DMSO) for 48 h was collected, and 30 µL from
each sample was used. Cytokine concentrations in the medium were determined using
the CBA Mouse Inflammation Kit (BD Sciences) according to the manufacturer’s
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instructions. Data were acquired using a BD LSR Fortessa flow cytometer (BD
Biosciences) and analyzed using FlowJo software (Treestar).

2.2.13 In vitro fermentation of human stool bacteria for 16S rRNA sequencing
Human fecal samples were collected from 8 individuals (4 male and 4 female,
age = 25-30 years, Asian, healthy, without pre-, pro-, or anti-biotics for at least 3
months). Bacteria from the samples were isolated and cultured at 37 oC in Gifu
Anaerobic (GAM) broth (HIMedia Laboratories, West Chester, PA), in an anaerobic
cabinet (Whitley A35 anaerobic workstation, Don Whitley Scientific, UK) under an
atmosphere of 85% N2, 10% CO2, and 5% H2. Bacteria were inoculated 1:10 (v/v)
into GAM broth containing TCS (0.1 and 1 µM) or 0.1% DMSO vehicle and incubated
at 37 oC in the anaerobic cabinet for 48 h. After incubation, bacteria were collected for
DNA extraction and 16S rRNA sequencing.

2.2.14 Microbial phylogenetic profiling by 16S rRNA sequencing
All PCR reactions were performed in a 96-well plate on a T100TM thermal
cycler (Bio-Rad) with 2X KAPA HiFi Hotstart ReadyMix (KAPA Biosystem,
Wilmington, MA). First, PCR was performed to amplify DNA of the bacterial
community with primers (see Table 2.1) that bound the V3-4 regions of the 16S rRNA
gene. The primers also incorporated the Illumina overhang adaptor. After purification
with AMPure XP beads (Beckman Coulter, Danvers, MA), limited cycle PCR was
performed using the Nextera XT Index Kit (Illumina, San Diego, CA) to attach dual
indices and Illumina sequencing adapters. After another purification with AMPure XP
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beads, the quantity of the purified PCR products was measured by Qubit dsDNA BR
Assay kit (Life Technology, Carlsbad, CA) and the amplicon quality was estimated by
ScreenTape Assay on Tape Station 2200 (Agilent Technologies, Santa
Clara, CA). Samples were then pooled in equimolar amount and pair-end 2*300bp
sequencing was performed using a MiSeq reagent kit V3 (5% PhiX) (Illumina, San
Diego, CA) on Illumina MiSeq platform. Sequencing was performed at Genomics
Resource Laboratory, University of Massachusetts Amherst.
Sequencing data was processed using the QIIMETM software pipeline v1.9.1
132

. Generally, the high- quality sequence data (quality value ≥ 30) was demultiplexed.

Sequences were then clustered into operational taxonomic unites (OTUs) using the
open reference OTU picking against Greengenes bacterial 16S rRNA database (13_8
release) with 97% similarity threshold. The α-diversity (the diversity within sample
community species richness) was determined with ten iterations at a maximal sequence
depth where all samples could be included.

2.2.15 Data and Statistical Analyses
Data are expressed as mean ± SEM. The statistical comparison of two groups
was analyzed using Student’s t-test. The statistical comparison of three or more groups
was analyzed using one-way ANOVA. The analysis of TCS metabolites in colon
digesta of mice (Figure 2.2) according to antibiotic treatment and TCS treatment was
performed using two-way ANOVA. The statistical analyses were performed using SAS
statistical software and SigmaPlot. P < 0.05 was considered statistically significant.
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2.3 Results
2.3.1

Profiles of TCS metabolites in mouse tissues
To our knowledge, detailed profiling of TCS metabolism in animal tissues has not

been attempted. To this end, we treated mice with TCS via diet for 4 weeks, then used
LC-MS/MS to profile TCS metabolites in various tissues. In agreement with previous
studies 123, we found that, in most organs, such as the liver, bile, heart, and small intestine
(mucosa and digesta), the dominant TCS metabolites were its glucuronide- and sulfateconjugates (Figure 2.1). However, in the digesta of the cecum and colon tissues, the
dominant metabolite was free-form TCS, with very low concentrations of the conjugates.
Indeed, the relative percentage of free-form TCS, TCS glucuronide, and TCS sulfate in
the colon digesta were 99.1 : 0.69 : 0.23 (Figure 2.1), illustrating a different profile of
TCS metabolism.

2.3.2

Role of gut microbiota in the colonic metabolism of TCS in mice
Compared with other organs such as the liver, a major difference of the colon

tissue is that the colon harbors a large number of gut bacteria 130. To determine whether
gut microbiota mediate the unique profile of TCS metabolism in the colon digesta, we
tested whether antibiotic cocktail-mediated suppression of gut microbiota alters TCS
metabolism in the colon digesta (see the scheme of the animal experiment in Figure
2.2A). We used an antibiotic cocktail from previous studies 133,134 and found that
treatment with the cocktail caused a dramatic reduction of fecal bacteria, as assessed by
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qPCR analysis of the 16S rRNA gene (Figure 2.3), validating the depleting effects of the
cocktail on gut microbiota.
We found that treatment with the antibiotic cocktail reduced the concentration of
free-form TCS (~50% reduction), while enhancing the concentration of TCS glucuronide
(~6-fold increase) and TCS sulfate (~5-fold increase) in the colon digesta (Figure 2.2B),
see complete LC-MS/MS results in Table 2.4). Two-way ANOVA analysis showed that
there was a significant interaction between antibiotic cocktail treatment (antibiotic
cocktail versus water) and TCS treatment (TCS versus vehicle) on both free-form TCS (P
< 0.001) and TCS-conjugates (P = 0.009). These results support that gut microbiota
mediate the conversion of TCS glucuronide and/or TCS sulfate conjugates to free-form
TCS, contributing to the colonic metabolism of TCS.
Using MS/MS-based fragmentation analysis, we also identified some novel
metabolites, including hydroxyl-TCS, hydroxyl-TCS glucuronide, and hydroxyl-TCS
sulfate, in the colon digesta (see mass spectrum of these compounds in Figure 2.4), and
found that the profiles of these metabolites were also dependent on gut microbiota.
Consistent with our results above, the antibiotic cocktail treatment reduced the
concentration of free-form hydroxyl-TCS while increasing the concentration of hydroxylTCS glucuronide and hydroxyl-TCS sulfate in the colon digesta (Figure 2.2C-E, see
complete LC-MS/MS results in Table 2.5). Two-way ANOVA analysis also showed that
there was a significant interaction between antibiotic cocktail treatment and TCS
treatment on these novel metabolites (P < 0.001 for all three metabolites). These results
further support the roles of gut microbiota in colonic metabolism of TCS.
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2.3.3

Effects of gut bacteria on the metabolism of TCS in vitro
To further validate the roles of gut microbiota in TCS metabolism, we cultured

gut bacteria under anaerobic conditions and studied their effects on TCS metabolism in
vitro. Our results above support that gut microbiota convert TCS glucuronide to freeform TCS in vivo (Figure 2.2), and we tested whether gut microbiota can directly catalyze
this reaction in vitro (see the scheme of the experiment in Figure 2.5A). With the
presence of gut microbiota from mice feces and human stool, TCS glucuronide was
converted to free-form TCS, while this reaction was not observed without the presence of
the bacteria (Figure 2.5B). These results support that the gut microbiota can catalyze the
de-glucuronidation reaction in vitro.
To explore the specific gut bacteria involved, we cultured pure bacteria strains
and tested their effects on TCS metabolism. Out of 12 strains, we found that 3 strains,
including Lactobacillus brevis, L. rhamnosus, and Bifidobacterium breve, were capable
of converting TCS glucuronide to free-form TCS in vitro (Figure 2.5C). Some strains,
such as L. reuteri (DSM 20053 and DSM 20016) and B. longum, showed no effect to
metabolize TCS glucuronide in vitro (Figure 2.5C). To validate that the lack of metabolic
activity was not due to suppressed bacterial growth, we tested the effects of TCS
glucuronide on bacterial growth and found that TCS glucuronide had no effect on
bacterial growth (Figure 2.6).
To better understand the interactions between TCS and TCS-metabolizing
bacteria (e.g. L. brevis, L. rhamnosus, and B. breve), we tested the effect of free-form
TCS on the growth of these bacterial strains. Compared with vehicle (DMSO), treatment
with TCS (concentration = 0.1-1 µM) did not affect bacterial growth in vitro (Figure 2.7).
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Next, we tested whether TCS exposure could change the abundance of these strains in
mouse gut microbiota. We used strain-specific primers 135,136 to perform qPCR analyses
and found that treatment with TCS (80 ppm in diet) for 4 weeks appeared to increase, but
not significantly, the relative abundance of these bacteria in mouse fecal microbiota
(Figure 2.8).
Besides the de-glucuronidation reaction, we also tested whether gut bacteria can
catalyze the conversion of TCS to hydroxyl-TCS. We incubated TCS with gut bacteria
from the small intestine, cecum, colon, and feces from the mice, as well as gut bacteria
from human stool. LC-MS/MS analysis showed no formation of hydroxyl-TCS (Table
2.6). This result suggests that at least the culturable gut bacteria cannot convert TCS to
hydroxyl-TCS in vitro.

2.3.4

Profiles of TCS metabolites in human subjects
We analyzed the profiles of TCS metabolites in the urine and stool of TCS-

exposed human subjects. To this end, we utilized human samples from a previous study
(ClinicalTrials.gov identifier NCT01509976), in which the human subjects were exposed
to TCS by using personal care products for up to 4 months (see scheme of experiment in
Figure 2.9A) 122.
LC-MS/MS showed that the dominant metabolites in human urine are the
conjugates: after 4 months of exposure, the relative percentages of TCS conjugates (a
combination of TCS glucuronide and TCS sulfate) and free-form TCS in the urine was
~99.5 : 0.5 (Figure 2.9B, see complete LC-MS/MS results in Table 2.7-8). However, in
the stool, the dominant metabolite is free-form TCS: after 4 months of exposure, the
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relative percentages of TCS conjugates and free-form TCS in the feces was ~1.7 : 98.3
(Figure 2.9C, see complete LC-MS/MS results in Table 2.9-10). These results are in
agreement with the mouse study as described above, which showed that colon digesta (or
feces) versus other tissues have distinct profiles of TCS metabolites.

2.3.5

Effects of TCS and its conjugates on inflammation in vitro
Our results above support that gut microbiota convert TCS conjugates to free-

form TCS in the colon. To explore the biological significance of the microbiota-mediated
metabolism, we studied the comparative effects of TCS conjugates (TCS glucuronide and
TCS sulfate) versus free-form TCS. We treated MC38 colon cancer cells with 1 µM of
each compound and studied the inflammatory responses. We determined the
concentration using our results above which showed that the concentration of free-form
TCS in the stool of TCS-exposed human subjects was up to ~1100 pmol/g (calculated to
be ~ 1 µM, see Figure 2.9C and Table 2.9). Using qRT-PCR analysis, we found that
treatment with TCS increased the gene expression of pro-inflammatory cytokines (Il6,
Ifng, Il1b, and Mcp1) in MC38 colon cancer cells, while TCS glucuronide and TCS
sulfate had no such effects (Figure 2.10A). Furthermore, ELISA analysis showed that
treatment with TCS, but not the conjugates, increased concentrations of pro-inflammatory
cytokines (IL-6, IFN-γ, and TNF-α) and reduced an anti-inflammatory cytokine IL-10 in
the medium of MC38 cells (Figure 2.10B). Together, these results suggest that the gut
microbiota convert TCS conjugates, which are biologically inactive, to generate freeform TCS, which has potent and direct pro-inflammatory effects, supporting the
biological significance of the microbiota-mediated metabolism.
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After demonstrating that free-form TCS had direct pro-inflammatory effects, we
further studied the direct effect of free-form TCS on gut microbiota in vitro. Previous
studies showed that exposure to TCS altered gut microbiota in animals and humans 65,116119,121

; however, it remains unknown whether TCS has a direct effect on gut microbiota.

We cultured human fecal microbiota derived from 8 healthy volunteers, treated with TCS
(concentration = 10 nM, which represents the low concentration of free-form TCS in the
stool of TCS-exposed human subjects, see Figure 2.9C and Table 2.9) or vehicle
(DMSO) under anaerobic conditions, then analyzed gut microbiota using 16S rRNA
sequencing (see scheme of experiment in Figure 2.11A). At this low concentration, TCS
treatment had no significant effect on the diversity of the microbiota (Figure 2.11B).
Regarding microbiota composition, TCS treatment altered bacterial abundance at both the
phylum and genus levels (Figure 2.11C-D and Figure 2.12). Notably, TCS treatment
increased the relative abundance of Proteobacteria, which is shown to be increased in
IBD patients and is positively associated with the pathogenesis of IBD (Figure 2.11D) 137.
Together, these results support that free-form TCS has a potent and direct effect of
altering gut microbiota, resulting in a potential pro-inflammatory phenotype.

2.4 Discussion
Previous research regarding the metabolism of TCS, as well as many other
environmental compounds, has only focused on the metabolic processes in mammalian
host tissues (e.g. liver), while the gut microbiota-mediated metabolism is understudied.
Notably, previous studies showed that after TCS enters the body, it is rapidly metabolized
by phase II detoxification enzymes, resulting in the formation of TCS glucuronide and
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TCS sulfate, which are water-soluble, biologically inactive, and are quickly removed
from the body 123. Here, our central finding is that gut microbiota catalyzes unique
metabolic conversions of TCS, resulting in colonic re-generation of free-form TCS
species which has potent and direct effects on both colon epithelial cells and gut bacteria
to induce a pro-inflammatory phenotype (see proposed model in Figure 2.13). This leads
to the accumulation of biologically active free-form TCS in the gut, and this could lead to
gut-specific toxic effects. These results highlight the critical importance of gut microbiota
in the metabolism and bioactivity of TCS. In addition, these results suggest that, besides
TCS, many other environmental chemicals could also be metabolically re-activated in the
gut by the actions of gut microbiota, resulting in the accumulation of microbiota-derived
toxic metabolites in the colon and leading to gut-specific toxicity.
Our results are in agreement with previous studies which showed that βglucuronidase-expressing gut bacteria could catalyze de-glucuronidation reactions 138.
We identified three strains of bacteria, including L. brevis, L. rhamnosus, and B. breve,
that were capable of converting TCS glucuronide to free-form TCS in vitro. This is
consistent with previous studies, which showed that these strains have expression of βglucuronidase 139-141. Interestingly, we found that some β-glucuronidase-expressing gut
bacteria, such as B. bifidum and L. gasseri 142,143, can’t convert TCS glucuronide to freeform TCS, suggesting that only specific β-glucuronidase isoforms recognize TCS
glucuronide as a substrate. It is feasible that, upon TCS exposure, individuals with
different profiles of gut bacteria or activities of gut metabolizing enzymes could have
varied colonic metabolism of TCS, resulting in inter-individual variations in biological
responses to TCS exposure. Notably, previous studies showed that the fecal β33

glucuronidase activity was significantly increased in colon cancer patients (~12-fold
increase of the enzymatic activity compared with healthy controls) 144, suggesting an
enhanced metabolic re-activation of TCS, which has colon cancer-enhancing effects 121,
in colon cancer patients. Elucidation of the roles of gut bacteria in the metabolism and
bioactivity of TCS could help to design better human studies to clarify the health impacts
of TCS.
Our results support that due to the unique metabolic reactions catalyzed by gut
microbiota (e.g. de-glucuronidation reaction), microbiota-derived toxic metabolites (e.g.
the free-form parent compound) could be accumulated in the gut tissues, resulting in gutspecific toxicity. This suggests that during an evaluation of the toxicology of
environmental toxicants and pollutants, it is of critical importance to study the
metabolism and toxicity in the gut tissues. Indeed, our recent study showed that TCS
exposure, at low doses, enhances basal colonic inflammation, increases the severity of
IBD, and exaggerates colon tumorigenesis in mice 121. Previous studies have shown that
TCS exposure could also cause adverse effects in other tissues such as liver 145; however,
it is noteworthy that the reported TCS doses to cause liver toxicity are higher than the
doses needed to exacerbate gut toxicity 121,145. This could be, at least in part, caused by
the different fate of TCS in the liver and gut tissues: in the liver, the dominant
metabolites are glucuronide- and sulfate-conjugates, which are usually biologically
inactive; in the gut, the dominant metabolites are free-form TCS species, which have
direct and potent effects on both colon epithelial cells and gut bacteria to induce a proinflammatory phenotype. Indeed, in our study, after a 4-week exposure to TCS in mice,
the average concentration of free-form TCS (the putative biologically active compound)
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was ~7.3 pmol/mg tissue in the liver versus ~282.8 pmol/g tissue in the colon digesta,
suggesting an accumulation of toxic compounds in the colon which could result in colonspecific toxicology. Besides TCS, many other environmental toxicants and pollutants
could also be metabolically re-activated by gut microbiota and result in gut-specific
toxicity, highlighting the critical importance of evaluating the impacts of environmental
exposure on gut health.
In summary, our results, using LC-MS/MS profiling in mouse models and human
subjects, as well as in vitro culture of gut bacteria, support that gut bacteria mediates
unique metabolic reactions of environmental toxicant TCS in the gut, resulting in
metabolic re-activation of TCS and potentially gut-specific toxicity. Based on our study,
it is of critical importance to better understand the toxicology of environmental toxicants
and pollutants in the gut tissues.
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Table 2.1. Sequences of primers for qPCR analysis.
Gene
Forward primer sequence
Gapdh
AGGTCGGTGTGAACGGATTTG
Il6
TAGTCCTTCCTACCCCAATTTCC
Ifng
ATGAACGCTACACACTGCATC
Il1b
GCAACTGTTCCTGAACTCAACT
Mcp1
TTAAAAACCTGGATCGGAACCAA
16S rRNA CCTACGGGTGGCTGCAG
B. breve
ATGGCAAAACCGGGCTGAA
L. brevis
CTTGCACTGATTTTAACA
Primers for sequencing
16S rRNA TCGTCGGCAGCGTCAGATGTGTAT
AAGAGACAGCCTACGGGNGGCWGC
AG
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Reverse primer sequence
TGTAGACCATGTAGTTGAGGTCA
TTGGTCCTTAGCCACTCCTTC
CCATCCTTTTGCCAGTTCCTC
ATCTTTTGGGGTCCGTCAACT
GCATTAGCTTCAGATTTACGGGT
GACTACTAGGGTATCTAATCC
GCGGATGAGAGGTGGG
GGGCGGTGTGTACAAGGC
GTCTCGTGGGCTCGGAGATGTGTA
TAAGAGACAGGACTACHVGGGTAT
CTAATCC

Table 2.2. Instrumental method for the quantification of TCS, TCS glucuronide,
and TCS sulfate.
Instrument

Thermo Scientific Dionex Ultimate 3000 UHPLC system coupled with
a TSQ Quantiva Triple Quadrupole Mass Spectrometer

Analytical column
and temperature

ACQUITY UPLC C18 column (1.7 μm particles, 2.1 mm × 100 mm,
Waters), 30 °C

Mobile phases

A. Acetonitrile

Gradient profile

Injection volume
MS scan mode

Time (min)
0.0
1.0
2.5
5.0
5.5
6.5
7.0
9.0

Percentage A (%)
15
15
80
80
100
100
15
15

Flow rate (mL/min)
0.30
0.30
0.30
0.30
0.30
0.30
0.30
0.30

10 μL
Multiple reaction monitoring (MRM)
Analytes
TCS

Monitored MRM
transitions

B. Ammonium acetate (2 mM) in water

MRM transition (m/z)
286.89 → 35.22
288.89 → 35.22

Collision Energy (eV)
16
16

299.00 → 35.22
301.00 → 35.22

16
16

TCS glucuronide

463.00 → 175.00
463.00 → 287.00

15
15

TCS sulfate

366.89 → 286.89
368.89 → 288.89

15
15

13C -TCS
12

Electrospray ionization (ESI): negative ionization mode;
Capillary voltage (kV) = 2.5;
MS/MS parameters Sheath gas (arbitrary units) = 40;
Auxiliary gas (arbitrary units) = 10;
Ion transfer tube temperature (°C) = 350;
Vaporizer temperature (°C) = 300.
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Table 2.3. Instrumental method for the identification of hydroxyl-TCS,
hydroxyl-TCS glucuronide, and hydroxyl-TCS sulfate.
Instrument
Analytical column
and temperature
Mobile phases

Gradient profile

Injection volume
MS scan mode

Thermo Scientific Dionex Ultimate 3000 UHPLC system coupled
with an Orbitrap Fusion Tribrid Mass Spectrometer (UHPLC–Orbitrap
Fusion MS)
ACQUITY UPLC HSS T3 column (1.7 μm particles, 2.1 mm × 100
mm, Waters), 30 °C
A. Methanol
B. Ammonium acetate (5 mM) in water
Time (min)
Percentage A (%)
Flow rate (mL/min)
0.0
10
0.30
1.0
10
0.30
6.0
80
0.30
9.0
80
0.30
10.0
100
0.30
12.0
100
0.30
12.5
10
0.30
15.0
10
0.30
10 μL
Targeted MS2
Analytes

Ion transitions for
metabolite
identification

Parent ion (m/z)

Product ion (m/z)

hydroxyl-TCS

302.9388

266.9627, 160.9561, 156.9703

hydroxyl-TCS
glucuronide

478.9709

hydroxyl-TCS
sulfate

382.8956
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302.9388, 266.9627, 175.0254,
160.9561, 156.9703, 113.0239
302.9388, 266.9627, 160.9561,
156.0703, 79.9574

Global MS parameters
Spray voltage (kV) = 3.0;
Sheath gas (arbitrary units) = 50;
Auxiliary gas (arbitrary units) = 15;
Ion transfer tube temperature (°C) = 285;
Vaporizer temperature (°C) = 300.
2
MS/MS parameters Targeted MS parameters
Isolation widow (m/z) = 0.8;
Activation type: high-energy collision dissociation (HCD);
HCD collision energy (%) = 25;
Orbitrap resolution = 30000;
Scan range (m/z) = 50–600;
Automated gain control (AGC) target = 5 × 10 4;
Maximum injection time (ms) = 100;
Polarity: Negative.
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Table 2.4 Concentrations of free-form TCS, TCS glucuronide, and TCS sulfate in mouse tissues after treatment.
See the scheme of animal experiment in Figure 2.2A. Statistical significance of the interaction effect between antibiotics treatment
(antibiotics versus water) and TCS treatment (TCS versus vehicle) on TCS metabolites was determined using two-way ANOVA.
Treatment
Vehicle

colon
digesta
colon
mucosa

TCS metabolites
(pmol/mg of tissue)
TCS
TCS glucuronide
TCS sulfate
TCS
TCS glucuronide
TCS sulfate
TCS

Antibiotics

TCS +
Antibiotics

TCS

Mean

SEM

Mean

SEM

Mean

SEM

0.59
0.00
0.00

0.06
0.00
0.00

0.35
0.01
0.01

0.08
0.00
0.00

288.27
0.79
1.74

19.69
0.30
0.24

0.19
0.00
0.06

0.03
0.00
0.02

0.12
0.01
0.24

0.01
0.00
0.08

7.02
0.19
7.85

0.67
0.15
0.60

0.26

0.06

0.19

small
intestine
digesta

TCS glucuronide
TCS sulfate

0.04
0.05

0.01
0.03

0.03
0.01

small
intestine
mucosa

TCS
TCS glucuronide
TCS sulfate

0.37
0.02
0.11

0.06
0.00
0.02

0.36
0.02
0.02

liver

TCS
TCS glucuronide

0.04
0.01

0.00
0.00

TCS sulfate
TCS

0.04
3.09

0.01
0.48

0.03 33.39
50.07
6.97

30.77
91.48
9.07

0.78
0.73
1.03
1.20

0.015
< 0.001
< 0.001
0.660
0.007
0.030

0.09 34.64
4.62
0.00
36.38
5.73
0.00
8.35
0.72

38.53 3.27
58.75
5.55
13.68
0.42

0.636
0.063
< 0.001

0.04
0.01

0.00
0.00

0.68
0.21

12.01
4.89

0.72
0.46

0.09
1.88

0.01 28.01
0.40 26.74

2.46
3.43

43.65
33.09

3.06
3.49

7.25
1.41

7.78
0.61

10.80
6.29
20.73

5.89
0.20

40

0.00
0.00

3.79

Interaction
SEM P-value
147.15 6.91
< 0.001
10.87
4.76
0.155
12.94
0.72
< 0.001

Mean

0.003
< 0.001
0.011
0.294

bile

heart

TCS glucuronide
TCS sulfate
TCS
TCS glucuronide
TCS sulfate

0.05
0.13
0.07
0.00
0.01

0.01
0.03
0.01
0.00
0.00

0.05
0.05
0.09
0.01
0.27
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0.01 142.27
0.01 69.40
0.01 0.90
0.01 1.23
0.18 8.79

22.13
5.26
0.10
0.15
0.52

276.15 35.60
105.20 6.41
0.66
0.06
2.14
0.37
11.83 0.37

0.036
0.006
0.137
0.122
0.006

Table 2.5. Peak areas of Hydroxyl-TCS, Hydroxyl-TCS glucuronide, and Hydroxyl-TCS sulfate in mouse tissues after
treatment.
See the scheme of animal experiment in Figure 2.2A). Statistical significance of the interaction effect between antibiotics treatment
(antibiotics versus water) and treatment (TCS versus vehicle) on Hydroxyl-TCS metabolites was determined using two-way ANOVA.

Vehicle
Hydroxyl-TCS
metabolites (Peak
area/mg of tissue)
colon
digesta
colon
mucosa
small
intestine
digesta
small
intestine
mucosa
liver

Hydroxyl-TCS
Hydroxyl-TCS glucuronide
Hydroxyl-TCS sulfate

Mean
24967
4009
21042

Antibiotics

SEM

Mean

SEM

11521
615
9132

1086
7623
24517

809
2358
7872

Treatment
TCS
Mean

SEM

31197734 2000424
5240
931
10358930 1906931

503
969808
2014 11665
10974 4478284

Mean

SEM

Interaction
P-value

3979604 611500
1693280 203969
36357272 3841162

< 0.001
< 0.001
< 0.001

722270
86344
1117236 202715
22891374 2897998

0.256
< 0.001
< 0.001

Hydroxyl-TCS
Hydroxyl-TCS glucuronide
Hydroxyl-TCS sulfate
Hydroxyl-TCS

1246
520
783
2064
1096 11146
168897 48036 76284
3193

1736

5087

Hydroxyl-TCS glucuronide
Hydroxyl-TCS sulfate
Hydroxyl-TCS

43482
27285
3602

7221
9900
2070

25840
45878
2294

12503 1857592 336104
7277 17836642 2684111
586
534201 140727

820610 60299
25807127 929018
151013 29716

0.048
0.063
0.077

Hydroxyl-TCS glucuronide
Hydroxyl-TCS sulfate
Hydroxyl-TCS
Hydroxyl-TCS glucuronide
Hydroxyl-TCS sulfate
Hydroxyl-TCS

7706
30006
1699
8150
5311
34884

1666
10757
1292
2117
1241
15102

8429
20404
4712
9799
5555
31577

2928
669202 110354
4350 11456388 1919544
1749
113643 31205
3547
167420 48614
484
2460621 446963
22358 347869 49864

158949
19445667
87821
28723
4353406
89741

0.005
0.055
0.550
0.056
0.050
0.004

2435
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887549

120281
3403
659995

TCS + Antibiotics

157038

133173

10319

30356
1993610
10827
3557
457273
22215

0.003

bile

heart

Hydroxyl-TCS glucuronide
Hydroxyl-TCS sulfate
Hydroxyl-TCS
Hydroxyl-TCS glucuronide
Hydroxyl-TCS sulfate

119330
111634
0
0
26081

40916 145415 44422 6850477 1635666
40925 53800 20338 40694806 1599612
0
0
0
0
0
0
0
0
0
0
5826
6891 3191
500701 58447
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1431632 211132 0.030
56083680 2120354 < 0.001
0
0
1.000
0
0
1.000
550402 36282
0.494

Table 2.6. LC-MS/MS analysis of TCS metabolism by gut bacteria.
Reaction product analyzed by LC-MS/MS
(expressed as peak area from MS)
Assay
Hydroxyl-TCS Hydroxyl-TCS Hydroxyl- TCS
glucuronide
sulfate
DMSO, w/o bacteria
<Limit of
<LOD
<LOD
detection (LOD)
DMSO, w/ mouse fecal bacteria <LOD
<LOD
<LOD
DMSO, w/ human stool bacteria <LOD
<LOD
<LOD
DMSO, w/ bacteria from mouse <LOD
<LOD
<LOD
small intestine
DMSO, w/ bacteria from mouse <LOD
<LOD
<LOD
cecum
DMSO, w/ bacteria from mouse <LOD
<LOD
<LOD
colon
TCS (20 µM dissolved
in DMSO), w/o bacteria

<LOD

<LOD

<LOD

TCS, w/ mouse fecal bacteria
<LOD
<LOD
<LOD
TCS, w/ human stool bacteria
<LOD
<LOD
<LOD
TCS, w/ bacteria from mouse
<LOD
<LOD
<LOD
small intestine
TCS, w/ bacteria from mouse
<LOD
<LOD
<LOD
cecum
TCS, w/ bacteria from mouse
<LOD
<LOD
<LOD
colon
Note: in all assays as shown above, we did not detect the formation of hydroxyl-TCS
species (while we successfully detected hydroxyl-TCS species in animal tissues, see
Figure 2.2), suggesting that at least the culturable bacteria can’t convert TCS to hydroxylTCS in vitro.
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Table 2.7. Concentrations of free-form TCS, TCS glucuronide, and TCS sulfate in
human urine after treatment.
See the scheme of the human experiment in Figure 2.9A.
TCS metabolites (pmol/μL urine)
Human
subject #

Treatment

Treatment
time (months)

5
9
16
14
7
5
6
7
9

no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS

0
0
0
1
3
4
4
4
4

< LOD *
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD

16

no TCS

4

3
4
8
12
12
12
13
3
4
13

TCS
TCS
TCS
TCS
TCS
TCS
TCS
TCS
TCS
TCS

0
0
0
0
1
2
3
4
4
4

TCS

TCS glucuronide

TCS sulfate

< LOD
5.52
0.04
0.41
0.02
< LOD
< LOD
< LOD
< LOD

< LOD
0.0016
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD

0.0642

0.71

< LOD

< LOD
< LOD
< LOD
< LOD
< LOD
0.0855
< LOD
0.1123
0.0552
0.0306

0.18
0.03
< LOD
0.13
6.26
9.53
7.71
13.73
7.75
10.37

0.0007
< LOD
< LOD
< LOD
0.0047
0.0052
0.0016
0.0069
0.0039
0.0026

* LOD: limit of detection
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Table 2.8. LC-MS/MS semi-quantification of hydroxyl-TCS, hydroxyl-TCS
glucuronide, and hydroxyl-TCS sulfate in human urine after treatment.
See the scheme of the human experiment in Figure 2.9A
TCS metabolites (Peak area/ μL urine)
Human
subject #

Treatment

Treatment
time (months)

5
9
16
14
7
5
6
7
9

no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
TCS
TCS
TCS
TCS
TCS
TCS
TCS
TCS
TCS
TCS

0
0
0
1
3
4
4
4
4

< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD

4
0
0
0
0
1
2
3
4
4
4

< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD

16
3
4
8
12
12
12
13
3
4
13

HydroxylTCS
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Hydroxyl-TCS
glucuronide

Hydroxyl-TCS
sulfate

< LOD
22627
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD

< LOD
68139
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD

< LOD
< LOD
< LOD
< LOD
< LOD
5683
31321
61177
106569
8887
53570

< LOD
< LOD
< LOD
< LOD
< LOD
49464
148435
161848
66047
28240
165006

Table 2.9. Concentrations of free-form TCS, TCS glucuronide, and TCS sulfate in human stool after treatment.
See the scheme of the human experiment in Figure 2.9A.
TCS metabolites (pmol/ g stool)
Human
subject #
2
5
6
7
9
11
14
16
2
5
6
7
9
11
14
16
5
6
7
9
11

Treatment

Treatment
time (months)

TCS

TCS glucuronide

no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS

0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
2
2
2
2
2

14.93
13.15
10.10
23.67
540.07
19.95
10.11
57.90
22.49
13.96
18.83
9.65
25.43
< LOD
14.00
317.47
22.69
29.34
19.95
14.40
< LOD

< LOD
5.21
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
4.99
21.75
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
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TCS sulfate
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD

14
16
2
5
6
7
9
11
14
16
2
5
6
7
9

no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS

2
2
3
3
3
3
3
3
3
3
4
4
4
4
4

56.73
96.24
11.79
7.44
< LOD
5.90
7.60
7.75
11.01
105.82
< LOD
20.54
< LOD
8.75
7.48
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< LOD
< LOD
17.62
< LOD
< LOD
< LOD
< LOD
< LOD
16.46
< LOD
< LOD
< LOD
< LOD
< LOD
14.59

< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD

Table 2.10. LC-MS/MS semi-quantification of hydroxyl-TCS, hydroxyl-TCS glucuronide, and hydroxyl-TCS sulfate in human
stool after treatment.
See the scheme of the human experiment in Figure 2.9A.
TCS metabolites (pmol/ g stool)
Subject #

Treatment

2
5
6
7
9
11
14
16
2
5
6
7
9
11
14
16
5
6
7

no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS

Treatment time Hydroxyl-TCS
(months)
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
2
2
2

< LOD
< LOD
< LOD
< LOD
10754
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
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Hydroxyl-TCS
glucuronide

Hydroxyl-TCS
sulfate

< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD

< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD

9
11
14
16
2
5
6
7
9
11
14
16
2
5
6
7

no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS
no TCS

2
2
2
2
3
3
3
3
3
3
3
3
4
4
4
4

< LOD
< LOD
< LOD
< LOD
2410
< LOD
< LOD
< LOD
554
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
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< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD

< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD
< LOD

Figure 2.1. Upon TCS exposure, the dominant metabolites in most organs are TCS
conjugates (TCS glucuronide and TCS sulfate), while the dominant compound in
the digesta of cecum and colon is free- from TCS.
(A) Chemical structures of TCS, TCS glucuronide, and TCS sulfate. (B) LC-MS/MS
quantification of the tissue concentrations of free-form TCS and TCS conjugates. SI:
small intestine. The data are mean ± SEM, n = 10 mice per group.
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Figure 2.2. Antibiotic cocktail-mediated suppression of gut microbiota reduces
concentrations of free-from TCS species, while enhancing concentrations of TCS
conjugates in colon digesta.
(A) Scheme of animal experiment. (B-E) LC-MS/MS quantification of (B) free-form
TCS, TCS conjugates (a combination of TCS glucuronide and TCS sulfate), (C)
hydroxyl-TCS, (D) hydroxyl-TCS glucuronide, and (E) hydroxyl-TCS sulfate in colon
digesta. The data are mean ± SEM, n = 5 mice per group for Veh or ABX group, and n =
10 mice per group for TCS or TCS + ABX group. Statistical significance of the
interaction effect between ABX (ABX versus water) and treatment (TCS versus vehicle)
on TCS species was determined by two-way ANOVA.
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Figure 2.3 Treatment with antibiotic cocktail (ABX) ablated bacteria in colons of
mice.
(A) Scheme of animal experiment (modified from Figure 2.2A): at day 0 (5 days after
ABX treatment) and day 28 (end of the experiment), the total fecal microbial biomass
was analyzed by qPCR of 16S rRNA gene. (B) 16S rRNA gene copies in mouse feces on
day 0 (n = 20 per group). (C) 16S rRNA gene copies in mouse feces on day 28 (n = 10
per group). The data are mean ± SEM, ***P < 0.001, **** P<0.0001.
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Figure 2.4. Identification of hydroxylated metabolites in colon digesta by UHPLCOrbitrap Fusion MS.
(A) Chromatogram of hydroxyl-TCS, hydroxyl-TCS glucuronide, and hydroxyl-TCS
sulfate. (B-D) Product ion spectra and proposed structures of m/z 302.9388
(hydroxyl-TCS, B), m/z 478.9709 (hydroxyl-TCS glucuronide, C), and m/z 382.8956
(hydroxyl-TCS sulfate, D).
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Figure 2.5. Gut bacteria mediates TCS metabolism in vitro.
(A) Scheme of experiment: TCS glucuronide was incubated with gut bacteria, and the
formation of free-form TCS was quantified by LC-MS/MS. (B) Effects of fecal
microbiota from mice or humans on converting TCS glucuronide to TCS. (C) Effects of
pure bacterial strains on converting TCS glucuronide to TCS. The data are mean ± SEM,
n = 3 per group, *P < 0.05, ***P < 0.001, ****P < 0.0001. Statistical significance was
determined using one-way ANOVA.
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Figure 2.6. TCS glucuronide treatment has no effect on bacterial growth.
Growth curves of L. brevis, L. rhamnosus, L. reuteri DSM 20053, L. reuteri DSM 20016,
and B. longum after 30 h treatment with vehicle or 20 µM TCS glucuronide. The data are
mean ± SEM, n = 3 from three independent experiments.
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Figure 2.7. TCS treatment has no effect on bacteria growth.
Growth curves of L. rhamnosus, L. gasseri, B. breve, B. bifidum and B.
pseudocatenulatum after 30 h treatment with vehicle, 0.1 µM, or 0.1 µM TCS. The data
are mean ± SEM, n = 3 from three independent experiments.
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Figure 2.8. Relative abundance of certain bacterial strains after exposure to TCS in
mice.
(A) Scheme of animal experiment (adapted from Figure 2.2A): the mice were treated with
TCS (80 ppm in diet) or vehicle via diet for 4 weeks, then the relative abundance of
certain bacterial strains in the mouse feces were analyzed by qPCR using strain-specific
primers. (B) The relative abundance of B. breve and L. brevis. The data are mean ± SEM,
n = 10 per group, statistical significance was determined using Student’s t-test.
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Figure 2.9. Upon TCS exposure, the dominant metabolites in human urine are TCS
conjugates, while the dominant compound in human stool is free-form TCS.
(A) Scheme of experiment: human subjects were exposed to personal care products
without TCS (control group), or exposed to personal care products containing TCS (TCS
group) for 4 months. At 0, 1, 2, 3, and 4 months, the urine and stool samples were
collected for analysis. (B) LC-MS/MS profiling of TCS metabolism in human urine. (C)
LC-MS/MS profiling of TCS metabolism in human stool. The data are mean ± SEM.
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Figure 2.10. TCS, but not TCS glucuronide or TCS sulfate, increases inflammatory
responses in MC38 colon cancer cells.
(A) Gene expression of inflammatory cytokines and (B) ELISA analysis of cytokines in
cell culture medium after treatment with vehicle, TCS, TCS glucuronide, or TCS sulfate
for 48 h. The data are mean ± SEM, n = 3 per group from three independent experiments,
* P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Statistical significance was
determined using one-way ANOVA.
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Figure 2.11. Effects of free-form TCS on human gut microbiota in vitro.
(A) Scheme of experiment. (B) Effects of TCS on diversity of human stool microbiota.
(C) Individual relative abundance at phylum level (n = 8 per group). C: control group
(treated with vehicle DMSO), T: treatment group (treated with 10 nM TCS). Volunteers
1-4 are male, and volunteers 5-8 are female. (D) Effect of TCS on relative abundance of
specific bacteria phylum (n = 8 per group). The Y-axis is expressed as relative abundance
of treatment group to control group for each individual volunteer. The results are mean ±
SEM, ** P < 0.01, *** P < 0.001.
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Figure 2.12. Exposure to TCS modulated composition of gut microbiota at genus
levels in human fecal bacteria in vitro.
(A) Individual relative abundance at genus level (n = 8 per group). C: control group
(treated with vehicle DMSO), T: treatment group (treated with 10 nM TCS). Volunteer 14 are male, and volunteer 5-8 are female. (B) Effect of TCS on relative abundance of
specific bacteria genera (n = 8 per group). The Y-axis is expressed as relative abundance
of treatment group to control group for each individual volunteer. The results are mean ±
SEM, ** P < 0.01, *** P < 0.001.
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Figure 2.13. Proposed model: gut bacteria mediates colonic metabolism of TCS,
leading to metabolic re- activation of TCS and resulting in enhanced colonic
inflammation.
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CHAPTER 3
TRICLOCARBAN EXPOSURE EXAGGERATES COLONIC INFLAMMATION
AND COLON TUMORIGENESIS BY ALTERING GUT MICROBIOTA

3.1 Introduction
Triclocarban (3,4,4'-trichlorocarbanilide, TCC) has been used as an antimicrobial
ingredient for more than 60 years, and is incorporated into many consumer products such
as bar soaps, deodorants and detergents 8. Each year, U.S. consumers are exposed to
approximate 500,000 pounds of TCC from personal care products 8. The 2013–2014
National Health and Nutrition Examination Survey showed that 36.9% of urine samples
in the United States contained TCC 146. The majority of used TCC is ultimately released
into the environment leading to widespread pollution. As a result, TCC was listed as a
top-10 contaminant in U.S. rivers 8. More alarmingly, recent studies showed that
environmental TCC could be efficiently taken up by food crops, leading to the
bioaccumulation of TCC and potential human exposure through food consumption.
Notably, Mathews et al. showed that some common food crops, such as broccoli, potato,
beat, cabbage, and pepper, can accumulate >100 ppm TCC in the root tissues, and onions
can accumulate >800 ppm TCC in the bulbs 147. The results from this study are supported
by many other investigations 148-155. Together, the ubiquitous presence of TCC has raised
concern about its impact on the environment and human health.
The regulatory policy of TCC is an intensively debated topic now. In 2016, the
FDA removed TCC from over-the-counter handwashing products 156. This decision was
mainly based on recent studies which showed that compared with plain soaps, the
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antimicrobial soaps containing TCC did not provide additional health benefits 157;
therefore, high-volume low-value use of TCC in handwashing products was not further
allowed by the FDA 156. This ruling only affects over-the-counter handwashing products,
but TCC remains approved by the FDA and the EPA for use in many other consumer
products. A better understanding of the impact of TCC on human health could be
important to prepare possible further regulatory policies of this compound.
Previous studies for TCC toxicology have focused on endocrine function 158-164,
however the effects of TCC on other human disorders are largely unknown. Our recent
studies showed that exposure to other consumer antimicrobials, such as triclosan,
benzalkonium chloride, and benzethonium chloride, exaggerates the severity of colitis
and exacerbates the development of colon tumorigenesis in mouse models, through gut
microbiota-dependent mechanisms 121,165. To date, the effects of TCC on gut health are
unknown. Here we studied the actions and mechanisms of TCC on colitis and colitisassociated colon tumorigenesis in animal models.

3.2 Materials and Methods
3.2.1

Animal experiments
All animal experiments were conducted in accordance with the protocol approved

by the Institutional Animal Care and Use Committee (IACUC) of the University of
Massachusetts Amherst. The mice were maintained in a standard specific-pathogen free
(SPF) animal facility. To facilitate the microbiota study, after mouse arrival, the mice
were rotated between different cages during the adaptation period, then the mice were
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randomized to different treatment groups (2-3 mice per cage). These procedures are
expected to mitigate potential cage effects on gut microbiota 166,167.

3.2.2

Dextran sodium sulfate (DSS)-induced colitis model
C57BL/6 male mice (six-week-old, Charles River, Wilmington, MA) were

randomly divided into control and treatment groups (n = 8 for each group). The mice in
the control group were treated with a modified AIN-93G diet (Table 3.1) containing 0.5%
v/w polyethylene glycol 400 (PEG 400, EMD Millipore, Billerica, MA), and the mice in
the treatment group were treated with the diet containing TCC (99%, Sigma-Aldrich, St.
Louis, MO) dissolved in PEG 400 during the whole experiment. After 3 weeks, the mice
were treated with 2% DSS (36–50 kDa, MP Biomedicals, Solon, OH) in drinking water
to induce acute colitis. After 9 days, the mice were sacrificed, and the blood and colon
tissues were collected for analysis.

3.2.3

Interleukin-10 (Il-10)-/- colitis model
Il-10-/- male mice (five-week-old, stock No. 002251, JAX, Bar Harbor, ME) were

randomly divided into control and treatment groups (n = 8 for each group). The mice
were fed with the modified AIN-93G diet containing PEG 400 (0.5% v/w) or 80 ppm
TCC dissolved in PEG 400 during the whole experiment. Standard sterilized water was
supplied in bottles ad libitum. After 12 weeks, the mice were treated with 200 ppm
piroxicam (Sigma-Aldrich, St. Louis, MO) via diet to accelerate development of colitis
168

. After 1 week, the mice were sacrificed, and the blood and colon tissues were

collected for analysis.
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3.2.4

Azoxymethane (AOM)/DSS-induced colorectal tumorigenesis model
C57BL/6 male mice (six-week-old) were acclimated for 1 week and randomized

into control and treatment groups (n = 16 for each group). The mice were fed with the
modified AIN-93G diet containing PEG 400 (0.5% v/w) or 80 ppm TCC dissolved in
PEG 400 during the whole experiment. After 3 weeks, the mice were treated with 10
mg/kg AOM (Sigma-Aldrich, St. Louis, MO) via intraperitoneal injection. After 1 week,
they were given 2% DSS in drinking water for 1 week. At day 50 post the AOM
injection, the mice were sacrificed, and the blood and colon tissues of the mice were
collected for analysis.

3.2.5

Antibiotic cocktail-mediated suppression of gut microbiota
C57BL/6 male mice (five-week-old) were treated with drinking water with or

without a broad-spectrum antibiotic cocktail (1.0 g/L ampicillin and 0.5 g/L neomycin)
during the whole experiment 133,134. After 4 days, the mice were treated with the modified
AIN-93G diet containing 80 ppm TCC or vehicle (PEG 400) until the end of the
experiment. After 3 weeks of diet treatment, the mice were stimulated with 2% DSS for 8
days in drinking water to induce colitis. At the end of the experiment, the mice were
sacrificed, and the blood and colon tissues were collected for analysis.

3.2.6

Flow cytometry analysis
The distal colon tissues from the mice were dissected, washed with cold PBS, and

digested with Hank's-balanced salt solution (HBSS, Lonza, Basel, Switzerland)
supplemented with 1 mM dithiothreitol (DTT) and 5 mM ethylenediaminetetraacetic acid
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(EDTA) for 2 h at 4 °C. The single cell suspensions were filtered through 70 μm cell
filters (BD Biosciences, San Jose, CA). The cells were stained with APC-conjugated antimouse CD11c antibody, FITC-conjugated anti-mouse CD45 antibody, PE/Cy7conjugated anti-mouse Ly-6G/Ly-6C (Gr-1) antibody, PerCP/Cy5.5-conjugated antimouse F4/80 antibody, and isotype control antibody according to the manufacturer’s
instructions (BioLegend, San Diego, CA). The stained cells were analyzed using BD
LSRFortessa™ cell analyzer (BD Biosciences, San Jose, CA) and data were analyzed
using FlowJo software (FlowJo LLC, Ashland, OR). In our analysis, leukocytes were
identified as CD45+ cells and macrophages were identified as CD45+ F4/80+ cells.

3.2.7

ELISA analysis of cytokines in plasma
The blood samples were harvested via cardiac puncture, and the plasma fractions

were prepared by centrifugation of the blood at 1,500 g for 10 min at 4 ˚C. The
concentrations of cytokines in plasma were determined using a CBA Mouse
Inflammation Kit (BD Biosciences) according to the manufacturer’s instruction.

3.2.8

RT-qPCR analysis
The colon tissues were frozen by liquid nitrogen and ground. Total RNA was

isolated from the colon tissues using TRIzol reagent (Ambion, Austin, TX) according to
the manufacturer’s instructions. The RNA was reverse transcribed into cDNA using a
High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA)
according to the manufacturer’s instruction. RT-qPCR was carried out with a DNA
Engine Opticon system (Bio-Rad Laboratories, Hercules, CA) with Maxima SYBR-green
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Master Mix (Thermo Fisher Scientific). The sequences of mouse-specific primers
(Thermo Fisher Scientific) were listed in Table 3.2. Glyceraldehyde-3-phosphate
dehydrogenase (Gapdh) was used as an internal control.

3.2.9

Hematoxylin and eosin (H&E) staining
The dissected colon tissues were fixed in 4% formalin (Thermo Fisher Scientific)

for 24 h, embedded into paraffin (Thermo Fisher Scientific), and sliced into 5-μm
sections. For H&E staining, the slides were stained with hematoxylin and eosin (SigmaAldrich), and examined with a light microscope. The histological scores were evaluated
by blind observers according to the crypt architecture, degree of inflammatory cell
infiltration, muscle thickening, and goblet cell depletion of the tissue. The histological
damage score is the sum of each individual score.

3.2.10 Immunohistochemistry (IHC)
The sections were prepared and heated in 0.01 M citrate buffer (pH 6.0) for 20
minutes in a PT Module antigen retrieval device (Thermo Fisher Scientific). The
antibodies against mouse PCNA and β-catenin (Cell Signaling Technology) were
incubated overnight at 4 °C. Horseradish peroxidase (HRP)-conjugated secondary
antibodies were then applied to the sections, followed by chromogen 4-diaminobenzidine
(Dako, Carpinteria, CA) staining. Sections were then counterstained with hematoxylin for
2 minutes. Positive expression was observed under a light microscope.
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3.2.11 16S rRNA sequencing of fecal microbiota
C57BL/6 male mice (six-week-old) were maintained on a modified AIN-93G diet
containing PEG 400 (0.5% v/w) or 80 ppm TCC dissolved in PEG 400 for 3 weeks. The
feces were collected for microbiota analysis. The total fecal DNA was extracted using
QIAamp DNA Stool Mini Kit (Qiagen) following the manufacturer’s instruction with the
addition of the bead-beating step. The quality of the extracted DNA was measured using
a NanoDrop Spectrophotometer (Thermo Scientific) and verified using gel
electrophoresis. PCRs were performed in a 96-well format on a Veriti thermal cycler
(Life Technology) with 2 × KAPA HiFi Hotstart ReadyMix (KAPA Biosystem) using
primers specific for the V3-V4 region of the 16s rRNA gene (see Table 3.2). After
purification with AMPure XP beads (Beckman Coulter), a limited cycle PCR was
performed using the Nextera XT Index Kit (Illumina) to attach dual indices and Illumina
sequencing adapters, followed by an additional purification with AMPure XP bead. The
quantity of the purified PCR products was measured using a Qubit dsDNA BR Assay kit
(Life technology) and the amplicon quality was estimated by ScreenTape Assay on Tape
Station 2200 (Agilent). After quantification and qualification, samples were pooled in
equimolar amount and pair-end 2*300bp sequencing was performed on an Illumina
MiSeq platform using a Miseq reagent kit V3 (8% PhiX) (Illumina). The sequencing data
was processed by QIIME software pipeline v1.9.1. In general, the high-quality sequence
data (quality value ≥ 30) was demultiplexed. Sequences were then clustered into
operational taxonomic unites (OTUs) using Open reference OTU picking against
Greengenes bacterial 16S rRNA database (13_8 release) with a 97% similarity threshold.
The α-diversity (the diversity within sample community species richness) was determined
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with ten iterations at a maximal sequence depth where all samples could be included. The
β-diversity (dissimilarity among different treatment groups) was calculated using
weighted and un-weighted UniFrac distances.

3.2.12 Culture of Bifidobacterium infantis 272
B. infantis 272 (ATCC, Manassas, VA) was subcultured at 37 °C in MRS broth
(Thermo Fisher Scientific) containing 0.5 g/L L-cysteine in an anaerobic cabinet
(Whitley A35 anaerobic workstation, Don Whitley Scientific, Shipley, England) under an
atmosphere of 85% N2, 10% CO2, and 5% H2. The B. infantis 272 were inoculated 1:100
into MRS broth containing TCC or DMSO vehicle and then incubated at 37 °C in
anaerobic conditions for 48 h. Bacterial growth was monitored by measuring the turbidity
at 600 nm.

3.2.13 Data analysis
Data are expressed as the mean ± standard error of the mean (SEM). Statistical
comparison of two groups was performed using Student’s t-test or Wilcoxon-MannWhitney test, and comparison of three or more groups was analyzed by one-way
ANOVA followed by Tukey’s post hoc test. Analysis of inflammation in antibioticstreated mouse experiments was performed by two-way ANOVA, followed by TukeyKramer’s method, and H&E histology data was analyzed by two-way ANOVA Poisson
Generalized Linear Model, followed by the Tukey-Kramer’s multiple comparison
method. P < 0.05 were considered statistically significant.
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3.3 Results
3.3.1

TCC increased DSS-induced colitis in mice
To determine the effect of TCC on colonic inflammation, we studied its effect on

colitis using a well-established DSS-induced colitis model in C57BL/6 mice 169.
Treatment with TCC via diet (80 ppm in diet, administering TCC at a dose of ~8
mg/kg/day, based on a diet of 3 g daily chow) exaggerated DSS-induced colitis in mice
(Figure 3.1). Compared with vehicle control, treatment with TCC exacerbated body
weight loss (Figure 3.1A), exacerbated colon length reduction (Figure 3.1B), increased
plasma concentrations of the pro-inflammatory cytokine IL-6 (Figure 3.1C), up-regulated
the gene expression of Il-6 in the colon (Figure 3.1D), increased infiltration of leukocytes
(CD45+) into the colon (Figure 3.1E), and exaggerated crypt damage in the colon (Figure
3.1F). We also tested the effect of a low-dose TCC (10 ppm in diet) and found that TCC
also exaggerated DSS-induced colitis (Figure 3.2). Together, these results demonstrate
the pro-colitis effect of TCC in vivo.

3.3.2

TCC increased colitis in Il-10-/- mice
To further validate the pro-colitis effect of TCC, we tested its action on

spontaneous colitis using a genetically engineered Il-10-/- mouse model 168. Treatment
with TCC via diet (80 ppm in diet, administering TCC at a dose of ~8 mg/kg/day, based
on a diet of 3 g daily chow) exaggerated colitis in Il-10-/- mice (Figure 3.3). Compared
with the vehicle control, treatment with TCC reduced the colon length (Figure 3.3A, P <
0.05), increased the gene expression of Il-6 in the colon (Figure 3.3B, P < 0.05),
enhanced infiltration of leukocytes (CD45+) into the colon (Figure 3.3C, P < 0.01), and
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exaggerated crypt damage in the colon (Figure 3.3D, P < 0.05). These results further
validate that exposure to TCC exaggerated colitis in vivo.

3.3.3

TCC increased AOM/DSS-induced colon tumorigenesis in mice
We tested the effect of TCC on colitis-associated colon tumorigenesis using a

well-established AOM/DSS-induced colon cancer model in C57BL/6 mice 170. Treatment
with TCC via diet (80 ppm in diet) increased AOM/DSS-induced colon tumorigenesis in
mice (Figure 3.4). Compared with the vehicle control, treatment with TCC reduced
overall survival of the mice (Figure 3.4A). Regarding colon tumorigenesis, TCC
increased the tumor number, tumor size, and total tumor burden in mice (Figure 3.4B, P
< 0.01), illustrating its pro-tumorigenic effect. Consistent with enhanced colon
tumorigenesis, immunohistochemical staining showed that TCC increased protein levels
of proliferating cell nuclear antigen (PCNA, a marker of tumor proliferation, P < 0.01)
and β-catenin (a marker of the pro-tumorigenic Wnt pathway, P < 0.001) in colon tumors
(Figure 3.4C). In addition, qRT-PCR showed that TCC treatment increased expressions
of c-Myc and Axin2 (markers of Wnt pathway) in colon tumors (Figure 3.4D, P < 0.05),
further supporting that TCC enhanced activation of the pro-tumorigenic Wnt pathway in
vivo. Inflammation plays a central role in colon tumorigenesis 171. Compared with the
vehicle control, TCC increased gene expressions of Il-6 and Tnf-α in colon tumors
(Figure 3.4D, P < 0.05), and enhanced infiltration of leukocytes (CD45+) and
macrophages (CD45+ F4/80+) into colon tumors (Figure 3.4E, P < 0.01), illustrating its
enhancing effect on tumor inflammation. Together, these results demonstrate that
exposure to TCC exaggerated colitis-associated colon tumorigenesis in vivo.
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3.3.4

TCC reduced the diversity and changed the composition of gut microbiota in
mice
Gut microbiota plays a central role in regulating colonic inflammation and colon

tumorigenesis 172. We studied the effect of TCC on gut microbiota in C57BL/6 mice.
Treatment with TCC via diet (80 ppm in diet) for 3 weeks decreased the a-diversity of
the gut microbiota, as assessed by PD-whole tree analysis (Figure 3.5A, P < 0.001), and
modulated the b-diversity of the microbiota, as assessed by principle coordinate analysis
(Figure 3.5B, P < 0.01). Regarding the composition of the gut microbiota, exposure to
TCC altered the relative bacterial abundance at both phylum and genus levels (Figure
3.5C-D, Table 3.3-3.4). Notably, TCC increased the abundance of Proteobacteria (Figure
3.5C, Table 3.3, P < 0.05), which has been shown to be increased in inflammatory bowel
disease (IBD) patients and is associated with the pathogenesis of IBD 137. TCC also
reduced the abundance of Bifidobacterium (Figure 3.5D, Table 3.4, P < 0.05), which has
been shown to have anti-inflammatory effects 173. Together, these results showed that
exposure to TCC could cause adverse effects on gut microbiota.

3.3.5

TCC inhibited growth of Bifidobacterium bacteria in vitro
Given our findings that TCC reduced the relative abundance of Bifidobacterium

in gut microbiota in vivo, we studied whether it could directly inhibit the growth of
Bifidobacterium in vitro. Compared with the vehicle control (DMSO), TCC at a
concentration of 100 nM inhibited ~30% of the growth of B. infantis 272 (Figure 3.6, P <
0.05). This result supports that TCC could have direct effects on gut bacteria.
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3.3.6

TCC increased DSS-induced colitis via gut microbiota-dependent
mechanisms
To validate the roles of gut microbiota in the biological actions of TCC, we tested

whether antibiotic cocktail-mediated suppression of gut microbiota modulates the procolitis effect of TCC (see scheme of animal experiment in Figure 3.7A). We used an
antibiotic cocktail from previous studies 133,134. We found that a 5-day treatment with this
cocktail caused a >99% reduction of fecal bacteria, as assessed by qPCR analysis of the
16S rRNA gene (Figure 3.8), validating that this antibiotic cocktail suppressed gut
microbiota. Before the DSS stimulation, treatment with TCC and/or the antibiotic
cocktail had little impact on mouse body weight (Figure 3.9).
Regarding DSS-induced colitis, two-way ANOVA analysis showed that there was
a significant interaction (P < 0.05) between TCC treatment (TCC versus vehicle) and
antibiotic treatment (antibiotic cocktail versus no antibiotic cocktail) on colonic
inflammation (Figure 3.7B-D). Notably, without antibiotic treatment, TCC exposure
enhanced crypt damage in the colon while, with antibiotic treatment, the pro-colitis effect
of TCC was abolished (Figure 3.7D). These results support that gut microbiota play a
critical role in the pro-colitis effect of TCC in vivo.

3.4 Discussion
To date, the effects of TCC on human health are not well understood. Previous
studies showed that TCC could be a potential endocrine-disrupting compound 158-164;
besides endocrine function, the effects of TCC on other human disorders are largely
unknown. Here our central finding is that exposure to TCC exaggerated colonic
inflammation and colitis-associated colon tumorigenesis in mice. We found that exposure
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to relatively low-dose TCC via diet (10-80 ppm in diet, administering TCC at a dose of
~1-8 mg/kg/day, based on a diet of 3 g daily chow) increased disease developments in
multiple animal models, including DSS-induced acute colitis in C57BL/6 WT mice,
spontaneous colitis in genetically engineered Il-10-/- mice, and AOM/DSS-induced colon
tumorigenesis in C57BL/6 WT mice, illustrating its pro-colitis and pro-neoplastic actions.
A previous study showed that the no-observed-adverse-effect-level (NOAEL) of TCC
was 75 mg/kg/day 174, which leads to a calculated acceptable daily intake (ADI) of TCC
to be 0.75 mg/kg/day. This ADI value is comparable to the dose used in our study, as we
showed that TCC at a dose of ~1 mg/kg/day exacerbated DSS-induced colitis in mice,
supporting the notion that the observed adverse effects of TCC in animal experiments
could mimic responses in human exposure to TCC. In addition, previous studies showed
that many common food crops could accumulate 100-800 ppm TCC 147, therefore, the
administration method (oral administration) and dose regime (10-80 ppm in diet) used in
our studies could reflect potential human exposure to TCC. We have to point out that
there are many challenges to using animal models to study human exposure to TCC: there
could be significant differences when exposed to TCC via oral intake (e.g. consumption
of TCC-contaminated water or food) or dermal application (e.g. usage of TCC-containing
washing products), and there could be significant inter-individual variations in exposure
level, absorption, and metabolism of TCC. Together, our results suggest that TCC could
be a novel environmental risk factor for IBD and colitis-associated colon cancer. Due to
the ubiquitous presence of TCC in our environment and possibly in our food system, it is
of critical importance to better understand the actions of TCC on IBD and colitis-
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associated colon cancer, in order to prepare for further regulation policies of this
compound.
Our studies support that gut microbiota contributes to the pro-colitis effects of
TCC. First, we found that exposure to TCC reduced the diversity of the gut microbiota in
mice. This finding is in agreement with a previous study which showed that exposure to
TCC caused dysbiosis in rats 175. Previous studies have constantly shown that compared
with healthy individuals, IBD patients have reduced diversity of gut microbiota,
suggesting that a reduction of microbial diversity could be correlated with adverse
outcomes of gut health 176. Second, we found that exposure to TCC increased abundance
of potentially harmful bacteria, and reduced abundance of beneficial bacteria in mouse
gut microbiota. Notably, TCC increased the abundance of Proteobacteria phylum, which
has been shown to be expanded in the gut microbiota of IBD patients, and associated with
the pathogenesis of IBD 137. In addition, TCC treatment caused a ~75% reduction of the
abundance of Bifidobacterium, which has been shown to have anti-inflammatory effects
173

. We further found that treatment with TCC at a concentration of 100 nM inhibited the

growth of B. infantis in vitro, suggesting that TCC could have a direct effect on
Bifidobacterium. Though there is no study of colonic concentrations of TCC in humans,
previous studies showed that after a routine usage of TCC-containing personal care
products, the blood concentrations of TCC in humans can reach up to ~500 nM 177,
supporting that the dose used in our in vitro experiment (100 nM) is biologically relevant.
The TCC-induced changes of Bifidobacterium and Proteobacteria are consistent with the
pro-colitis effect of TCC, but more studies are needed to validate the contributions of
these gut bacteria in the biological actions of TCC. Finally, we showed that TCC failed to
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promote DSS-induced colitis in antibiotic cocktail-treated mice, supporting that gut
microbiota is required for the pro-colitis effect of TCC. We have to mention that there are
limitations to using the antibiotic cocktail strategy to study the roles of gut microbiota
involved 178. More studies are needed to elucidate the functional roles of gut microbiota,
as well as the mucosal immunity, in the biological actions of TCC.
In summary, here our studies showed that exposure to TCC, a widely used
antimicrobial ingredient and a ubiquitous contaminant in the environment, exaggerated
colonic inflammation and colitis-associated colon tumorigenesis in mice, through the
modulation of gut microbiota. These results showed that TCC could be a novel risk factor
for IBD and colon cancer. Further studies are needed to better characterize the impact of
TCC exposure on gastrointestinal diseases in humans in order to prepare for possible
further regulation of this compound.
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Table 3.1. Composition of the modified AIN-93G diet used in the animal
experiment.
Ingredients
Casein

g/kg
200

L-cystine
Sucrose
Dyetrose
Cornstarch
Cellulose
Mineral mix #210025
Vitamin mix #310025
Choline Bitartrate
Corn oil (purified) *
Vitamin A Palmitate

3
100
132
397.486
50
35
10
2.5
70
0.016

* All ingredients, except corn oil, were purchased from Dyets Inc (Bethlehem, PA).
Because many commercial corn oil was already oxidized with varied degrees of lipid
peroxidation, we used purified corn oil for our animal experiment. Briefly, commercial
corn oil (Mazola®, ACH Food company, Inc., Cordova, TN) was purchased from a local
market in Amherst, MA, and purified by a silicic acid-activated charcoal chromatography
to remove any pre-existing oxidized compounds, then the purified oil was fortified with
400 ppm tocopherols, flushed with N2, and stored at -80°C until use.
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Table 3.2. Sequences of primers in qRT-PCR and 16S rRNA sequencing.
Gene
Gapdh
Tnf-α
Il-6
Ifnγ
Tlr4
Il-10
Il-1β
C-myc
Axin 2
16s rRNA

Forward
AGGTCGGTGTGAACGGATTTG
CCCTCACACTCAGATCATCTTCT
TAGTCCTTCCTACCCCAATTTCC
ATGAACGCTACACACTGCATC
ATGGCATGGCTTACACCACC
GCTCTTACTGACTGGCATGAG
GCAACTGTTCCTGAACTCAACT
TGAAGTTCACGTTGAGGGG
TGCATCTCTCTCTGGAGCTG
TCGTCGGCAGCGTCAGATGTGTA
TAAGAGACAGCCTACGGGNGGC
WGCAG

80

Reverse
TGTAGACCATGTAGTTGAGGTCA
GCTACGACGTGGGCTACAG
TTGGTCCTTAGCCACTCCTTC
CCATCCTTTTGCCAGTTCCTC
GAGGCCAATTTTGTCTCCACA
CGCAGCTCTAGGAGCATGTG
ATCTTTTGGGGTCCGTCAACT
AGAGCTCCTCGAGCTGTTTG
ACTGACCGACGATTCCATGT
GTCTCGTGGGCTCGGAGATGTGTAT
AAGAGACAGGACTACHVGGGTATC
TAATCC

Table 3.3. Effects of TCC on composition of the microbiota at phylum levels.
(* P < 0.05, ** P < 0.01, *** P < 0.001). Results expressed as relative abundance (%).
Phylum Name
Unassigned
Actinobacteria
Bacteroidetes
Cyanobacteria
Deferribacteres
Firmicutes
Proteobacteria
Tenericutes
Verrucomicrobia

Ctrl
Average
1.290
3.505
52.984
0.734
1.686
38.873
0.385
0.031
0.511

SEM
0.111
0.930
1.841
0.163
0.478
1.670
0.096
0.004
0.193
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TCC
Average
0.547
1.091
32.209
0.137
0.004
62.104
2.048
0.054
1.806

***
**
***
***
***
***

SEM
0.092
0.509
5.054
0.079
0.002
4.437
0.567
0.027
1.231

Table 3.4. Effects of TCC on composition of the microbiota at genus levels.
The results are expressed as relative abundance (%). (* P < 0.05, ** P < 0.01, *** P <
0.001)
Ctrl

TCC

Genus Name
Unassigned
Prauseria
Bifidobacterium
Adlercreutzia
Eggerthella
o Bacteroidales;Other;Other
Bacteroides
Parabacteroides
f Rikenellaceae;g
f S24-7;g
Butyricimonas
o YS2;f ;g
Mucispirillum
f Bacillaceae;g
Staphylococcus
Enterococcus
Lactobacillus
Streptococcus
Turicibacter
o Clostridiales;Other;Other
o Clostridiales;f ;g
f Christensenellaceae;g
f Clostridiaceae;Other
f Clostridiaceae;g
Clostridium
Dehalobacterium
f Lachnospiraceae;Other
f Lachnospiraceae;g
Anaerostipes
Blautia
Coprococcus
Dorea
Pseudobutyrivibrio
Roseburia
[Ruminococcus]
f Peptococcaceae;g
rc4-4
f Peptostreptococcaceae;g_
_
f Ruminococcaceae;Other
f Ruminococcaceae;g

Average
1.290
0.004
3.352
0.145
0.000
0.022
19.876
13.855
0.336
13.529
5.362
0.734
1.686
0.015
0.004
0.020
5.887
0.008
0.139
0.037
11.102
0.110
0.014
0.081
0.009
0.232
0.339
3.937
0.002
0.001
0.251
0.273
0.037
0.013
0.528
0.058
1.163

SEM
0.111
0.001
0.922
0.014
0.000
0.007
2.123
2.009
0.053
3.403
0.358
0.163
0.478
0.002
0.002
0.007
1.179
0.001
0.053
0.008
1.453
0.014
0.010
0.015
0.002
0.027
0.064
0.554
0.000
0.000
0.024
0.117
0.009
0.007
0.047
0.012
0.269

Average
0.547
0.012
0.889
0.159
0.019
0.002
17.980
10.540
0.224
0.004
3.451
0.137
0.004
0.058
0.117
0.036
2.831
0.097
0.008
0.070
22.917
0.084
0.002
0.390
0.013
0.061
0.330
7.393
0.011
0.003
0.771
0.541
0.007
0.016
1.369
0.046
1.762

0.010
0.806
3.514

0.006
0.091
0.390

0.027
0.875
7.578
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***
**
*
*
***

***
***
***
*

*
*
*
**
*
**
***
**
*
***
*
**
***

**

SEM
0.092
0.004
0.490
0.034
0.012
0.001
2.163
2.958
0.065
0.002
0.935
0.079
0.002
0.021
0.108
0.023
1.644
0.086
0.007
0.012
3.528
0.020
0.002
0.112
0.003
0.017
0.025
1.097
0.003
0.001
0.128
0.134
0.004
0.006
0.211
0.017
0.962
0.027
0.169
1.361

Anaerotruncus
Oscillospira
Ruminococcus
f [Mogibacteriaceae];g
o SHA-98;f ;g
f Erysipelotrichaceae;Other
f Erysipelotrichaceae;g
Clostridium
Coprobacillus
o RF32;f ;g
Burkholderia
f Oxalobacteraceae;Other
f Enterobacteriaceae;Other
f Enterobacteriaceae;g
Enterobacter
Klebsiella
Stenotrophomonas
o RF39;f ;g
Akkermansia

0.013
5.521
3.863
0.031
0.002
0.019
0.795
0.026
0.007
0.125
0.019
0.006
0.000
0.164
0.048
0.000
0.006
0.031
0.511

0.004
0.531
0.422
0.005
0.001
0.006
0.140
0.006
0.003
0.040
0.002
0.001
0.000
0.038
0.031
0.000
0.001
0.004
0.193
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0.019
6.877
6.806
0.017
0.000
0.011
0.873
0.027
0.044
0.199
0.082
0.016
0.004
1.395
0.123
0.187
0.008
0.054
1.806

*

***
**
***
**

0.007
0.851
2.216
0.004
0.000
0.003
0.179
0.006
0.025
0.092
0.044
0.004
0.002
0.458
0.050
0.127
0.002
0.027
1.231

Figure 3.1. TCC increased DSS-induced colonic inflammation in C57BL/6 mice.
(A) Body weight. Left: time-course of body weight; Right: quantification of mouse body
weight on the final day. (B) Colon length. (C) Concentration of IL-6 in plasma. (D) Gene
expression of Il-6 in colon. (E) FACS quantification of immune cell infiltration into the
colon. (F) H&E staining of the colon. The data are mean ± SEM, * P < 0.05, ** P < 0.01,
n = 8 mice per group.
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Figure 3.2. Effect of a lower-dose TCC (10 ppm in diet) on DSS-induced colitis in
mice.
(A) Body weight. Left: time-course of body weight; Right: quantification of mouse body
weight on the final day. (B) Colon length. (C) Concentration of IL-6 in plasma. (D) Gene
expression of Il-6 in colon. (E) FACS quantification of immune cell infiltration into
colon. (F) H&E staining of the colon. The data are mean ± SEM, * P < 0.05, ** P < 0.01,
n = 8 mice per group.
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Figure 3.3. TCC increased the colonic inflammation in Il-10-/- mice.
(A) Colon length. (B) Gene expression of Il-6 in colon. (C) FACS quantification of
immune cell infiltration into the colon. (D) H&E staining of the colon. The data are mean
± SEM, * P < 0.05, ** P < 0.01, n = 8 mice per group.
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Figure 3.4. TCC increased AOM/DSS-induced colon cancer in C57BL/6 mice.
(A) Survival curve. (B) Quantification of colon tumors in mice. (C) IHC staining of
PCNA and β-catenin in colon tumors. (D) Gene expressions in colon tumors. (E) FACS
quantification of immune cell infiltration into colon tumors. The data are mean ± SEM, *
P < 0.05, ** P < 0.01, *** P < 0.001, n = 16 mice per group.
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Figure 3.5. TCC reduced the diversity and altered the composition of gut microbiota
in C57BL/6 mice.
(A) α-diversity of the gut microbiota. (B) β-diversity of the gut microbiota, calculated by
Principle Coordinate Analysis (PCoA) based on weighted UniFrac distance. (C) Relative
abundance of gut bacteria at phylum levels. (D) Relative abundance of gut bacteria at
genus levels. The data are mean ± SEM, *** P < 0.01, n = 16 mice per group.

88

Figure 3.6. Effect of TCC on B. infantis 272 growth.
B. Infantis 272 was treated with TCC or vehicle (DMSO) under anaerobic conditions for
48 h, then bacterial growth was analyzed by measuring the turbidity at 600 nm. The
results are expressed as mean ± SEM, from three independent experiments conducted in
triplicates, * P < 0.05, ** P < 0.01.
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Figure 3.7. TCC increased DSS-induced colitis via gut microbiota-dependent
mechanisms.
(A) Scheme of animal experiment. (B) Colon length. (C) FACS quantification of immune
cell infiltration into colon. (D) H&E staining of colon. The data are mean ± SEM. The
statistical significance (P-value) of the interaction effect between TCC treatment (TCC
versus vehicle control in the diet) and antibiotic treatment (antibiotic cocktail versus no
antibiotic cocktail in the drinking water) on colitis was determined by two-way ANOVA
analysis. * P < 0.05, ** P < 0.01, *** P < 0.001, n = 8-10 mice per group.
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Figure 3.8. Effect of the antibiotic cocktail on fecal bacterial load.
The mice were given drinking water with or without the antibiotic cocktail (1.0 g/L
ampicillin and 0.5 g/L neomycin) for 5 days. Feces were collected and 16S rRNA gene
expression in feces were analyzed by qRT-PCR (n = 7 per group). The results are
expressed as mean ± SEM, ** P < 0.01.
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Figure 3.9. Effect of TCC and/or antibiotic cocktail on mouse body weight
Before the DSS stimulation. The results are expressed as mean ± SEM.
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CHAPTER 4
EFFECTS OF CONSUMER ANTIMICROBIALS BENZALKONIUM
CHLORIDE, BENZETHONIUM CHLORIDE, AMD CHLOROXYLENOL ON
COLONIC INFLAMMATION AND COLITIS-ASSOCIATED COLON
TUMORIGENESIS IN MICE

4.1 Introduction
Benzalkonium chloride (BAC), benzethonium chloride (BET), and chloroxylenol
(PCMX) are chemicals used in high-volume as antimicrobial and antibacterial ingredients
in many consumer, industrial, and medical products, including eye and nasal drops,
soaps, mouthwash, and cosmetics. Previous studies have shown that these compounds are
generally well-tolerated in animal models, though there are reports that these compounds
could cause adverse effects, such as inflammatory responses and genotoxic effects 8385,179

, mitochondrial dysfunction 180, reproductive dysfunction 81, and developmental

defects 181. Recent studies show that these compounds, partly due to their high-volume
use, are frequently detected in river water, sewage effluent, food products, and human
samples of plasma and serum 37-45. This has raised concern about their impact on the
environment and human health. In September 2016, the U.S. Food and Drug
Administration (FDA) removed 19 antimicrobial compounds from consumer antiseptic
wash products, but deferred rulemaking for BAC, BET, and PCMX to allow additional
time to develop new safety and efficacy data for these three antimicrobials 156. Therefore,
it is of critical importance to better understand the effects of these compounds on human
health, producing knowledge that could have a significant impact on regulatory policies.
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Inflammatory bowel disease (IBD) is characterized by colonic inflammation, and
given that it affects ~1.6 million people in the U.S. and ~2.5 million people in Europe 182,
IBD is a serious health problem in developed countries. IBD patients have elevated risks
of developing colon cancer: it was estimated that over 20% of IBD patients could develop
colon cancer within 30 years of diagnosis, and over 50% of these patients could die from
colon cancer 2. Previous studies performed in cultured cells showed that exposure to these
compounds caused inflammatory responses and genotoxic effects in vitro 83-85. However,
to date, the effects of BAC, BET, and PCMX on inflammation and associated
tumorigenesis in vivo are unknown. Here, we studied the impact of these three
antimicrobial compounds on colonic inflammation and colitis-associated colon
tumorigenesis using mouse models. Our results demonstrated that exposure to low doses
of these antimicrobial compounds, in particular BAC, increased dextran sodium sulfate
(DSS)-induced colonic inflammation and azoxymethane (AOM)/DSS-induced colon
tumorigenesis in mice, suggesting that these antimicrobial compounds could have
potentially adverse effects on gut health.

4.2 Materials and Methods
4.2.1

Chemicals
BAC (purity ≥95%, catalog # AC215411000), BET (purity 97%, catalog #

AC215411000), and PCMX (purity >98.5%, catalog # AC109061000) were purchased
from Thermo Fisher Scientific (Waltham, MA). Polyethylene glycol 400 (PEG 400,
catalog # PX1286B-2) was purchased from EMD Millipore (Billerica, MA).
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4.2.2

Animal experiments
C57BL/6 male mice (age = 6 weeks) were purchased from Charles River

(Wilmington, MA) and were maintained in a standard Specific Pathogen Free (SPF)
animal facility at the University of Massachusetts Amherst. All animal procedures were
conducted in accordance with protocols approved by the Institutional Animal Care and
Use Committee (IACUC) of the University of Massachusetts. At Charles River, bleachand chlorine dioxide-based disinfectants are used in the animal facility; and at UMass,
hydrogen peroxide-based disinfectants are used to clean surfaces in the animal facility
(biological safety cabinets, etc.) and BAC-containing products are used to clean the floor
of the animal facility. Therefore, there is little or no exposure of the mice to
environmental BAC or other antimicrobials.

4.2.3

DSS-induced colitis model
C57BL/6 mice were administered a modified AIN-93G diet (see diet composition

in Table 4.1) containing 80 ppm BAC, BET, or PCMX (administered at a dose of ~8
mg/kg body weight/day, based on a diet of 3 g daily chow), or vehicle control (0.5%
Polyethylene glycol 400) throughout the whole experiment. The diets were mixed
thoroughly so that the compounds were distributed evenly and changed every 3-4 days.
After 3 weeks on the diet, the mice were treated with 2% DSS (molecular weight in the
range of 36–50 kDa, MP Biomedicals, Solon, OH) in drinking water for 7 days to induce
colonic inflammation. At the end of DSS treatment, the mice were sacrificed for analysis
of colonic inflammation.
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4.2.4

Dose-response study of BAC on DSS-induced colitis
C57BL/6 mice were administered a modified AIN-93G diet containing 5-40 ppm

BAC (administered at a dose of ~0.5-4 mg/kg body weight/day, based on a diet of 3 g
daily chow), or vehicle control throughout the whole experiment. After 3 weeks on the
diet, the mice were treated with 2% DSS in water for 7 days to induce colonic
inflammation. At the end of DSS treatment, the mice were sacrificed for analysis of
colonic inflammation.

4.2.5

AOM/DSS-induced colitis-associated colon cancer model
The mice were administered a diet containing 40 ppm BAC (administered at a

dose of ~4 mg/kg body weight/day, based on a diet of 3 g daily chow) or vehicle
throughout the whole experiment. The diets were mixed thoroughly so that the
compounds were distributed evenly and changed every 3-4 days. After 3 weeks on the
diet, the mice were given intraperitoneal (i.p.) injection of 10 mg/kg AOM (SigmaAldrich, St. Louis, MO). After 1 week, they were treated with 2% DSS in water for 1
week. On day 50 post the AOM injection, the mice were sacrificed, and blood and colon
tissues of the mice were collected for analysis.

4.2.6

Flow cytometry analysis of immune cell infiltration into colon tissues
Distal colon tissues of the treated mice were dissected, washed with cold PBS,

and digested with Hank's-balanced salt solution (HBSS, Lonza, Basel, Switzerland)
supplemented with 1 mM dithiothreitol (DTT) and 5 mM ethylenediaminetetraacetic acid
(EDTA) for 2 h at 4 °C. The released cells were filtered through 70 μm cell sorters (BD
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Biosciences, San Jose, CA) to obtain single cell suspensions, which were stained with
FITC-conjugated anti-mouse CD45 antibody, PE/Cy7-conjugated anti-mouse Ly-6G/Ly6C (Gr-1) antibody, PerCP/Cy5.5-conjugated anti-mouse F4/80 antibody, and isotype
control antibody (BioLegend, San Diego, CA). The stained cells were analyzed using a
BD LSRFortessa™ cell analyzer (BD Biosciences, San Jose, CA), and data were
analyzed using the FlowJo software (FlowJo LLC, Ashland, OR). The leukocytes were
identified as CD45+ cells, neutrophils were identified as CD45+, Gr1+ cells, and
macrophages were identified as CD45+, F4/80+ cells. Percentages of cells were
calculated based on total single cells released from distal colon tissues.

4.2.7

ELISA analysis of cytokines
Colon tissues were cut open longitudinally, washed with PBS buffer containing

penicillin (100 U/mL) and streptomycin (100 μg/mL) (Lonza, Basel, Switzerland). Distal
colon tissues (25 mg) were placed in RPMI 1640 medium (Thermo Fisher Scientific)
with 10% fetal bovine serum (FBS, EMD Millipore, Temecula, CA) supplemented with
penicillin (100 U/mL) and streptomycin (100 μg/mL), and incubated at 37 °C in an
atmosphere containing 5% CO2 for 24 h. The supernatants were collected, and cytokines
in the supernatant were measured by the CBA Mouse Inflammation Kit (BD Biosciences)
according to the manufacturer’s instruction.
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4.2.8

Hematoxylin and Eosin (H&E) staining
Dissected colon tissues were cut open longitudinally, washed in ice-cold PBS and

fixed in 4% formalin (Thermo Fisher Scientific) at 4 °C. Tissues were gradually
incubated with 15% and 30% sucrose (Thermo Fisher Scientific) at 4 °C, then embedded
in optimal cutting temperature (OCT) compound (Fisher Healthcare, Houston, TX) and
frozen for cryosectioning. OCT-fixed tissue specimens were sliced into 5 μm sections,
mounted on glass slides, and air-dried for one hour. Sections were stained with H&E
staining (Sigma-Aldrich) and examined with light microscopy. The histological scores
were evaluated by a blinded observer and given scores according to the following
measures: crypt architecture (scored 0-3 with 0 as normal and 3 as most crypt distortion
and loss); inflammatory cell infiltration (0-3 with 0 as normal and 3 as most dense
inflammatory infiltrate); muscle thickening (0-3 with 0 as normal and 3 being most
muscle thickness); goblet cell depletion (0-1 with 0 as goblet cells present and 1 goblet
cells depleted) and crypt abscess (0-1 with 0 as absent and 1 present). The histological
score is the sum of each score.

4.2.9

Immunohistochemistry
Formalin-fixed tissue was embedded in paraffin by using TissueWave™ 2

Microwave Processor (Thermo Fisher Scientific), sliced to 5 µm sections on the same
slide, dewaxed in serial xylene solutions (Thermo Fisher Scientific), and rehydrated
through graded ethanol solutions (Pharmco-Aaper, Shelbyville, KY). Antigen retrieval
was performed by heating the sections in 0.01 M citrate buffer (pH 6.0) to 95°C for 10
minutes. Samples were incubated with anti-PCNA antibody (Dako, Carpinteria, CA),
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anti-cleaved caspase-3 antibody (Cell Signaling Technology, Danvers, MA), anti-βcatenin antibody (BD Biosciences) overnight at 4 °C. Horseradish peroxidase (HRP)conjugated secondary antibodies were then applied to the sections, followed by the
chromogen 4-diaminobenzidine staining according to the instruction of HRP/DAB
(ABC) Detection IHC kit (Abcam, Cambridge, MA). Sections were then counterstained
with hematoxylin for 1 min. Positive expression of PCNA, cleaved caspase-3 and βcatenin were observed under light microscope and scored using Fiji software 183. Briefly,
images of the IHC stained tissues were uploaded to Fiji, and the color was deconvoluted.
The intensity numbers of the “Colour_2” image (brown staining) were converted to
Optical Density (OD) numbers and then scored relative to control.

4.2.10 Quantitative reverse-transcriptase DNA polymerase chain reaction (qRTPCR) analysis
Distal colon tissues (20 mg) were ground using liquid nitrogen. Total RNA was
isolated from the colon tissues using TRIzol reagent (Ambion, Austin, TX) according to
the manufacturer’s instructions. The RNA was reverse transcribed into cDNA using a
High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster City, CA)
according to manufacturer’s instructions. qRT-PCR was carried out with a DNA Engine
Opticon system (Bio-Rad Laboratories, Hercules, CA) with PowerUpTM SYBRTM Green
Master Mix (Thermo Fisher Scientific). The sequences of mouse-specific primers
(Thermo Fisher Scientific) are listed in Table 4.2. Glyceraldehyde-3-phosphate
dehydrogenase (Gapdh) expression was used as an internal control.
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4.2.11 Toll-like receptor 4 (TLR4) reporter cell assay
HEK-Blue™ mTLR4 cells (InvivoGen, San Diego, CA) were cultured in DMEM
medium supplemented with 10% FBS and HEK-Blue™ Selection solution (InvivoGen, a
mixture of antibiotics to maintain the expression of transgenes in HEK-Blue™ mTLR4
cells) and incubated in a 37 °C incubator under an atmosphere of 5% CO2, according to
the manufacturer’s instructions. Briefly, to determine activation of TLR4, 20 μL of
mouse plasma sample, and 180 μL of 2 x 104 HEK-Blue™ mTLR4 cells suspended in
HEK-BlueTM Detection medium, was added into each well of 96-well plate. After
incubation at 37 oC for 16 h, the production of secreted embryonic alkaline phosphatase
(SEAP) was assessed by reading the absorbance at 620 nm with a plate reader (Molecular
Devices, Sunnyvale, CA).

4.2.12 Quantification of LPS in plasma
Plasma LPS levels were quantified using the LPS ELISA kit (MBS261904,
MyBiosource, San Diego, CA) following the manufacturer’s instructions.

4.2.13 Real-time PCR (qPCR) analysis of 16S rRNA gene in liver
DNA was extracted from mouse liver samples (~25 mg) using QIAamp DNeasy
Blood & Tissue Kit (Qiagen, Valencia, CA) following the manufacturer’s instruction
with the addition of the bead-beating step. The quality of the extracted DNA was
measured using a NanoDrop Spectrophotometer (Thermo Fisher Scientific). DNA was
subjected to qPCR analysis using a DNA Engine Opticon system (Bio-Rad Laboratories,
Hercules, CA) with PowerUpTM SYBRTM Green Master Mix (Thermo Fisher Scientific).
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DNA was normalized to 5 ng/μL per reaction. The sequences the 16S rRNA primers
(Thermo Fisher Scientific) are listed in Table 4.2.

4.2.14 Data analysis
Data are expressed as the mean ± standard error of the mean (SEM). Group
comparisons were carried out using one-way analysis of variance (ANOVA) or Student ttest. P values less than 0.05 were considered statistically significant.

4.3 Results
4.3.1

Exposure to BAC and BET exaggerated DSS-induced colitis in mice
To study the effects of these antimicrobials on colonic inflammation, we used a

well-established DSS-induced colitis model in mice. We treated mice with BAC, BET,
PCMX (80 ppm in the diet), or vehicle via diet for 21 days. During this period, treatment
with the antimicrobial alone did not affect the mouse body weight (Figure 4.1). We then
stimulated the mice with 2% DSS in drinking water for 7 days to induce colonic
inflammation (see scheme of animal experiment in Figure 4.2).
Exposure to BAC and BET, but not PCMX, increased DSS-induced colonic
inflammation in mice. Compared with vehicle-treated DSS mice, the BAC-treated DSS
mice showed increased weight loss on days 6-7 after initiation of DSS stimulation (P <
0.05), while BET and PCMX had no such effect (Figure 4.2B). Exposure to all three
antimicrobial compounds caused a reduction in colon length (P < 0.001, Figure 4.2C),
which is a biomarker of colitis. Histology analysis showed that exposure to BAC and
BET, but not PCMX, increased DSS-induced colonic inflammation, with increased crypt
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damage and inflammatory cell infiltration into colon tissues (P < 0.05, Figure 4.2D). We
next analyzed the colon at the cellular and molecular level. Immune cells and cytokines
play critical roles in the development of colitis 2. Flow cytometry analysis showed that
exposure to BAC and BET, but not PCMX, increased infiltration of immune cells–
including leukocytes (CD45+), macrophages (CD45+, F4/80+), and neutrophils (CD45+,
Gr1+)–into colon tissues (P < 0.05, Figure 4.2E). ELISA analysis showed that exposure
to BAC and BET, but not PCMX, increased concentrations of interleukin 6 (IL-6), a proinflammatory cytokine, in colonic explant (P < 0.05, Figure 4.2F). Consistent with the
ELISA result, qRT-PCR analysis showed that exposure to BAC increased gene
expression of Il-6 in colon tissues (P < 0.01); BET also increased Il-6 expression, but the
effect was not statistically significant, and PCMX had no effect (Figure 4.2G). These
results suggest that BAC and BET, but not PCMX, were able to increase DSS-induced
colonic inflammation.

4.3.2

Dose-dependent effects of BAC on DSS-induced colitis in mice
Among the three compounds, BAC showed the most potent effect on DSS-

induced colonic inflammation, and we further studied its dose-dependent effect on
colonic inflammation (see scheme of animal experiment in Figure 4.3A). The results
showed that exposure to 20-40 ppm of BAC in the diet (~2-4 mg/kg body weight/day)
caused a reduction in colon length (P < 0.05, Figure 4.3B). Flow cytometry analysis
showed that exposure to BAC increased immune cell infiltration into the colon in a dosedependent manner (Figure 4.3C). These results suggest that even at lower doses, BAC
was able to increase DSS-induced colonic inflammation.
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4.3.3

Exposure to BAC exaggerated AOM/DSS-induced colon tumorigenesis in
mice
After demonstrating that exposure to BAC showed the most potent effect on DSS-

induced colonic inflammation, we studied its effect on colitis-associated colon
tumorigenesis using an AOM/DSS-induced colon tumorigenesis model in mice (see
scheme of animal experiment in Figure 4.4A). Compared with vehicle-treated mice, the
mice treated with BAC had increased mortality: the overall mortality for the control
group was 21% (3 out of 14 mice died in the control group), and mortality for the BAC
group was 60% (9 out of 15 mice died in BAC group) (Figure 4.4B). Exposure to BAC
increased the spleen weight, suggesting increased systemic inflammation: the spleen
weight of vehicle-treated mice was 135 ± 14 mg (mean ± SEM) versus 191 ± 20 mg for
BAC-treated mice (P < 0.05, Figure 4.4C). Exposure to BAC also increased the average
tumor size (1.8 ± 0.3 cm2 for the control group versus 3.5 ± 0.5 cm2 for the BAC group, P
= 0.008), yet had no effect on the numbers of tumors per mouse (8.6 ± 1.3 for the control
group versus 10 ± 1.8 for the BAC group, P = 0.539), although the total tumor burden in
mice did increase (14.8 ± 3.7 cm2 for the control group versus 35 ± 8.8 cm2 for BAC
group, P = 0.033) (Figure 4.4D). The qRT-PCR analysis showed that treatment with
BAC increased the gene expressions of several pro-tumorigenic genes, such as c-Jun,
cyclin D, and β-catenin, in colon tumors (P < 0.05, Figure 4.4E). Consistent with the
qRT-PCR result, immunohistochemistry showed that β-catenin protein levels were
increased in colon tumors of BAC-treated mice (P < 0.01). In addition, we found that the
proliferating cell nuclear antigen (PCNA) protein levels were increased (P < 0.01), while
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cleaved caspase-3 protein levels were decreased (P<0.001), in BAC-treated colon tumors,
which suggests that exposure to BAC increased tumor proliferation and decreased tumor
apoptosis (Figure 4.4F). Together, these results demonstrate that exposure to BAC
increased AOM/DSS-induced colitis-associated colon tumorigenesis in mice.

4.3.4

Exposure to BAC increased activation of Toll-like receptor 4 (TLR4) in
systemic circulation
Innate immunity receptors, in particular TLR4, play critical roles in regulating

colonic inflammation and associated colon tumorigenesis 184,185. We studied the effects of
BAC exposure on TLR4 signaling, by testing the potential of the plasma from BACtreated DSS mice on the activation of TLR4. Using a TLR4 reporter cell line (HEKBlue™ mTLR4), we found that, compared with the plasma from vehicle-treated DSS
mice, the plasma from BAC-treated DSS mice caused enhanced activation of TLR4 (P =
0.013, Figure 4.5A). Consistent with the TLR4 reporter assay, we found that the BACtreated DSS mice had higher plasma levels of LPS, a known ligand of TLR4 (P = 0.040,
Figure 4.5B) 186. In addition, we found that the liver tissues from BAC-treated DSS mice
had higher levels of bacterial DNA, as assessed by qPCR analysis of 16S rRNA gene (P =
0.064, Figure 4.5C). These results demonstrate that exposure to BAC enhanced
translocation of bacterial products from the gut into the circulation and other organs.
Previous studies showed that an enhanced level of bacterial products in the systemic
circulation could be due to compromised mucosal permeability 187. Therefore, we tested
the effect of BAC exposure on the expression of colonic proteins involved in regulating
intestinal barrier function. We found that compared with vehicle-treated DSS mice, the
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BAC-treated DSS mice had a dramatic reduction of colonic expression of Occludin (P =
0.006, Figure 4.5D), which encodes a protein that plays an important role in maintaining
mucosal barrier function 188. Together, these results showed that exposure to BAC
enhanced activation of TLR4 in the systemic circulation, in part through impairing
intestinal barrier function and enhancing bacterial products in the circulation.

4.4 Discussion
In the last century, there has been a dramatic increase in the incidence and
prevalence of IBD in the United States and other countries 1. This rapid development
suggests that environmental factors could contribute to the growing incidence of IBD
around the globe 3-5. In support of this hypothesis, recent studies showed that exposure to
certain dietary and environmental compounds increased the development of IBD in
animal models 4,5. Due to the increased incidences of IBD and the potential lethal
consequence of IBD-associated colon cancer, it is of practical importance to discover
new environmental risk factors for these diseases.
BAC, BET, and PCMX are antimicrobial compounds used in many consumer
products. Previous studies showed that these compounds could cause some adverse
effects, including inflammatory responses and genotoxic effects 83-85,179, mitochondrial
dysfunction 180, reproductive dysfunction 81, and developmental defects 181. In this study,
we studied their effects on IBD and IBD-associated colon tumorigenesis in mouse
models. Here, our central finding is that short-term exposure to low-dose antimicrobial
compounds, in particular BAC and BET, increased colitis and/or colitis-associated colon
tumorigenesis in mice, which suggests potential adverse effects from these compounds.
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Among the tested three compounds, PCMX showed the least severe adverse effect;
however, in the DSS colitis experiment, exposure to PCMX also increased DSS-induced
colon length reduction. This suggests some adverse effects on gut health may result from
PCMX. Our results are in agreement with previous studies that illustrated proinflammatory effects of BAC in vitro. These studies showed that treatment with BAC
increased production of pro-inflammatory cytokines in immortalized human conjunctival
and corneal epithelial cells, and increased phagocytosis, macrophage migration, and
production of pro-inflammatory cytokines in THP-1-derived macrophages 83,84.
Therefore, the enhancing effects of BAC on colitis and colitis-associated colon cancer
could be, at least in part, due to its pro-inflammatory effect. To our knowledge, this study
is the first animal study to demonstrate that these antimicrobial compounds have adverse
effects on gut health. A better understanding of their actions on colonic inflammation and
colon cancer could help to establish regulatory policies for these compounds.
Among the three tested antimicrobial compounds, PCMX showed the least
adverse effect on DSS-induced colitis, with little impact on colonic inflammation. There
could be several reasons for the different effects of PCMX compared to BAC and BET.
PCMX, but not BAC and BET, contains a phenolic group, which is highly prone to rapid
metabolism by phase II detoxification enzymes such as glucuronosyltransferase and
sulfotransferase, leading to formation of water-soluble conjugated metabolites
(glucuronides and sulfates) and excretion via the urine. Indeed, previous studies in dogs
showed that PCMX was rapidly metabolized to glucuronide- and sulfate- conjugates and
excreted in urine 189. Therefore, the lack of effect of PCMX on colonic inflammation in
our studies could be in part due to its poor metabolic stability. In addition, compared with
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BAC and BET, PCMX has a much smaller size, which could impact its absorption and
duration in the gastrointestinal tract. To date, the metabolism and pharmacokinetics of
these antimicrobial compounds in vivo are not well investigated. Further studies could
help to address the structure-activity relationships of the antimicrobials, which could help
to design better antimicrobial ingredients.
A critical question in this study is whether the effects observed in the animal
models represent responses that would arise from human exposure. An examination of
the comparability of our administered dosage to investigated Acceptable Daily Intake
(ADI) levels can shed light on this question. In our experiment, we found that exposure to
40 ppm of BAC in diet (administering BAC at a dose of ~4 mg/kg/day, based on a diet of
3 g daily chow) increased colitis-associated colon tumorigenesis in mice. The dose used
in our animal experiment is the lowest among reported animal studies of BAC 42,190. To
put the dose in perspective, previous studies showed that the No-Observed-AdverseEffect Level (NOAEL) of BAC was 192 mg/kg body weight/day from a 90-day study in
CD-1 mice 191, which leads to a calculated ADI of BAC of ~1.9 mg/kg body weight/day
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. Therefore, the dose of BAC used in the animal experiments is comparable to

previously investigated ADI values. This supports the biological relevance of our
findings. We recognize the difficulties in translating the animal data to human studies.
There are several challenges to using animal models to study human exposure to these
consumer antimicrobial compounds. First, accurate assessment of the degree, type, and
variation of exposure levels of these compounds in humans is largely lacking. Second,
dermal exposure (e.g. by using soaps) and oral exposure (e.g. by using mouthwash or
toothpaste) to these antimicrobial compounds could lead to different biological responses.
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Indeed, a recent study showed that usage of antibacterial toothpaste, but not antibacterial
soaps, modulated gut microbiota in humans 193. Third, after exposure to these
compounds, there could be a high degree of inter-individual variation in the metabolism
and secretion of these compounds. Based on our studies, it is feasible to conclude that
long-term high-dose exposure to these antimicrobial compounds could lead to adverse
effects on gut health. Previous studies have shown that BAC and BET were frequently
detected at high levels in grapefruit seed extract (GSE), a popular dietary supplement,
despite the fact that these compounds are not permitted to use as food additives 37,38.
Notably, von Woedtke et al. showed that five out of six commercial GSE products
contained 1.3-10% of BET. Frequent consumption of these contaminated dietary products
could lead to high-dose exposure to BET and might cause adverse effects on gut health.
TLRs are important innate immunity receptors and play critical roles in regulating
colonic inflammation and associated colon tumorigenesis 2,194. Our results showed that
during DSS-induced colitis, exposure to BAC impaired intestinal barrier function and
thus enhanced translocation of bacterial products (e.g. LPS and bacteria) from the gut
into the systemic circulation and other organs, resulting in enhanced activation of TLR4
in the systemic circulation. Previous studies showed that enhanced activation of TLR4 is
associated with increased progression of colitis and colitis-associated colon cancer
185,195,196

. Indeed, compared with WT mice, genetically-engineered mice lacking TLR4

had attenuated, while genetically-engineered mice with overexpression of TLR4 had
enhanced, the progression of DSS-induced colitis and/or AOM/DSS-induced colon
cancer 184,195,196, though there are inconsistent results 197. Together, these results support
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that TLR4 signaling might play a role in the observed pro-colitis and pro-neoplastic
effects of BAC.
In summary, our study showed that exposure to low-dose antimicrobial
compounds, particularly BAC, increased colonic inflammation and colon cancer in mice.
These studies suggest that further studies are needed to better characterize the effects of
these compounds on gut health in order to develop sound regulatory policies for these
compounds.
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Table 4.1. Composition of the modified AIN-93G diet used in the animal
experiments.
Ingredients
g/kg
Casein
200
L-cystine
3
Sucrose
100
Dyetrose
132
Cornstarch
397.486
Cellulose
50
Mineral mix #210025
35
Vitamin mix #310025
10
Choline bitartrate
2.5
Corn oil (purified) *
70
Vitamin A palmitate
0.016
* All ingredients, except corn oil, were purchased from Dyets Inc (Bethlehem, PA). Because
commercial corn oil was already oxidized with varied degrees of lipid peroxidation, we used
purified corn oil for our animal experiments. Briefly, commercial corn oil was purchased from a
local market in Amherst, MA, and purified by a silicic acid-activated charcoal chromatography to
remove any pre-existing oxidized compounds 198, then the purified oil was fortified with 400 ppm
tocopherols, flushed with N2, and stored at -80°C until use.

110

Table 4.2. Sequences of primers in qRT-PCR and qPCR.
Gene
Gapdh

Forward
AGGTCGGTGTGAACGGATTTG

Reverse
TGTAGACCATGTAGTTGAGGTCA

Il-6

TAGTCCTTCCTACCCCAATTTCC

TTGGTCCTTAGCCACTCCTTC

Tlr4

ATGGCATGGCTTACACCACC

GAGGCCAATTTTGTCTCCACA

Axin2

TGCATCTCTCTCTGGAGCTG

ACTGACCGACGATTCCATGT

C-Jun

CCTTCTACGACGATGCCCTC

GGTTCAAGGTCATGCTCTGTTT

Ki67

ATCATTGACCGCTCCTTTAGGT

GCTCGCCTTGATGGTTCCT

C-myc

TGAAGTTCACGTTGAGGGG

AGAGCTCCTCGAGCTGTTTG

CyclinD
Wnt2
β-catenin

GCGTACCCTGACACCAATCTC
CTCGGTGGAATCTGGCTCTG
CAGCTTGAGTAGCCATTGTCC

CTCCTCTTCGCACTTCTGCTC
CACATTGTCACACATCACCCT
GAGCCGTCAGTGCAGGAG

Occludin

ACGGACCCTGACCACTATGA

TCAGCAGCAGCCATGTACTC

16S rRNA

TCGTCGGCAGCGTCAGATGTGTAT
AAGAGACAGCCTACGGGNGGCWGC
AG

GTCTCGTGGGCTCGGAGATGTGTATA
AGAGACAGGACTACHVGGGTATCTAA
TCC
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Figure 4.1. Effect of BAC, BET, and PCMX on mice body weight.
The results are expressed as mean ± SEM.
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Figure 4.2. Effects of BAC, BET, and PCMX on DSS-induced colitis in C57BL/6
mice.
(A) Scheme of animal experiment. (B) Body weight. (C) Colon length. (D)
Representative images of H&E staining of colon sections and histological score. (E)
Quantification of immune cell infiltration into colon tissues. (F) ELISA analysis of IL-6
in colonic explant. (G) Gene expression of Il-6 in colon tissues. The results are expressed
as mean ± SEM, n = 12 mice per group, * P < 0.05, ** P < 0.01, *** P < 0.001.
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Figure 4.3. Dose-response effect of BAC on DSS-induced colonic inflammation in
mice.
(A) Scheme of animal experiment. (B) Colon length. (C) Flow cytometry analysis of
immune cells in colon tissues. The results are expressed as mean ± SEM, n = 8 mice per
group, * P < 0.05, ** P < 0.01.
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Figure 4.4. Effect of BAC on AOM/DSS-induced colitis-associated colon cancer in
C57BL/6 mice.
(A) Scheme of animal experiment. (B) Survival rate. (C) Spleen weight. (D)
Representative images of colon tumors and quantification of colon tumorigenesis. (E)
qRT-PCR analysis of gene expressions in colon tumors. (F) Representative images of
immunohistochemical staining (magnification ×300) of β-catenin, PCNA, cleaved
caspase 3, and H&E, and quantification of immunohistochemical images. The results are
expressed as mean ± SEM, n = 14-15 mice per group, * P < 0.05, ** P < 0.01, *** P <
0.001.
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Figure 4.5. BAC exposure increased TLR4 activation in the systemic circulation.
(A) TLR4 reporter assay of the plasma from BAC- or vehicle-treated DSS mice. (B)
Concentration of LPS in plasma. (C) Expression of 16S rRNA gene in liver. (D) qRTPCR analysis of gene expression of Occludin in colon. The results are expressed as mean
± SEM, n = 10-12 mice per group.
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CHAPTER 5
CONCLUSIONS AND FUTURE DIRECTIONS

IBD has become a serious health problem since its incidence and prevalence has
dramatically increased throughout the world. Antimicrobials used in consumer products
might serve as environmental risk factors for IBD and its associated diseases. TCS, TCC,
BAC, BET, and PCMX are widely used antimicrobial ingredients in consumer products
and are ubiquitous contaminants in the environment. In 2016, the FDA removed TCS and
TCC from over-the-counter handwashing products while allowing additional time to
develop new safety and efficacy data for BAC, BET, and PCMX. Therefore, it is
important and timely to better understand the effects of these antimicrobials on human
health. Currently, there is not much known about how chronic exposure to low-dose
consumer antimicrobials affects gut health. Here, we validated the effects and
mechanisms of triclosan, as well as other consumer antimicrobials, and the gut
microbiome on IBD using three studies.
First, we showed that TCS was metabolically re-activated in the gut by the actions
of gut microbiota, leading to the accumulation of microbiota-derived toxic metabolites in
the colon and resulting in gut-specific toxicity. Upon TCS exposure, the dominant
metabolites of TCS in host tissues were its glucuronide- and sulfate- conjugates, which
are biologically inactive; however, in the colon digesta, the dominant metabolites were
free-form TCS species, which have potent and direct effects on both colon epithelial cells
and gut bacteria to induce a pro-inflammatory phenotype. This unique profile of TCS
metabolism in the colon digesta was disrupted by treatment with an antibiotic cocktail.
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Furthermore, gut microbiota from mice and humans, as well as specific bacteria strains
(Lactobacillus brevis, L. rhamnosus, and Bifidobacterium breve), catalyzed TCS
biotransformation in vitro, supporting that gut microbiota mediates TCS metabolism.
Second, we showed that exposure to low-dose TCC exaggerated the severity of
colitis and exacerbated the development of colitis-associated colon tumorigenesis, via gut
microbiota-dependent mechanisms. Exposure to TCC increased DSS- and IL-10
knockout- induced colitis, and exaggerated AOM/DSS-induced colon tumorigenesis in
mice. Regarding its mechanisms, TCC exposure reduced the diversity, altered the
composition of gut microbiota, and failed to promote DSS-induced colitis in mice lacking
the microbiota, supporting that the presence of the microbiota is critical for the pro-colitis
effects of TCC.
Finally, we reported that exposure to low doses of BAC, BET, and PCMX increased
DSS-induced colonic inflammation, and BAC increased AOM/DSS-induced colon
tumorigenesis in mice. In addition, we find that exposure to BAC increases activation of
TLR4 signaling in the systemic circulation, by disrupting intestinal barrier function and
thus enhancing circulating levels of bacterial products.
Our studies support that the gut microbiome is required for the pro-inflammatory
effects of these antimicrobials. However, the functional roles of the microbiome, as well
as the specific gut bacteria, involved in the biological actions of these antimicrobials are
unknown. Elucidation of the specific bacteria involved will help to design human studies
to validate the impact of antimicrobial exposure on human health and clarify potential
inter-individual variations in metabolism and responses to their exposure.
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The regulatory policy of TCS, as well as other antimicrobials, is an intensively
debated topic now. Our study, as well as the research from other laboratories, support that
TCS and other widely-used antimicrobials could have adverse effects on the gut
microbiome and gut health. More studies are needed to better characterize the impact of
these compounds on gut health in humans.
There are still more experiments needed to evaluate TCS on gut health. In our
study, we treated mice with TCS, and other antimicrobials, for several weeks. Because
humans could potentially be exposed to TCS for many years, it is worth pursuing an
animal study exposing mice for several months, or longer to further mimic human
exposure to TCS. This would be especially interesting due to the fact that we see
dramatically enhanced colon damage (>2-fold in the histological score) in mice exposed
to TCS for only a relatively short time of 3 weeks 121. In addition to exposing mice for a
longer period, another potential experiment is to expose mice to TCS for a few weeks and
then stop exposure for another several weeks to see if this removal of TCS would
decrease TCS-enhanced colitis. This is based a previous study which showed that the
modulation of the gut microbiomes of TCS-exposed and unexposed fathead minnows
disappeared after 2 weeks of depuration 116; this suggests that the modulation caused by
TCS may disappear after removal of TCS, which may in turn lead to a decrease in TCSenhanced colitis.
It would be ideal to further investigate the identification of which specific bacteria
contribute to TCS-enhanced colitis, and whether this is due to TCS promoting
antibacterial resistance in specific microbes. There has been concern of TCS promoting
antibacterial resistance in specific microbes 199, and some of the studies previously
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discussed support this: in zebrafish, the abundance of microbes that are resistant to TCS
was increased in the TCS-exposed groups 117; in infants, there was a positive correlation
between urinary TCS levels and Proteobacteria species which is a group associated with
an increase in antibiotic resistance genes in the gut microbiota 65; and in mice, TCS also
appeared to enrich genes in bacteria that are involved in TCS resistance, multidrug
resistance efflux pumps, and bacterial stress when exposed to mice 8.
Together, our results suggest that these widely used antimicrobial compounds could
exaggerate disease development of inflammatory bowel disease and associated colon
cancer. Further studies are urgently needed to better characterize the impacts of these
compounds on gut diseases in order to develop sound regulatory policies for these
compounds.
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